key figure millions chf figure report figure report financial statement adjust basisa change change sale ebitdab operating profit net income research development addition property plant equipment personnel number employee december ratio ebitda sale operate profit sale net income sale research development sale datum share nonvoting equity security chf earning share nonvoting equity security dilute dividend share nonvoting equity securityc adjust figure present improve comparability current future consolidated result recur accounting effect new revise international accounting standard effective january acquisition remain outstanding share genentech june take place begin furthermore exclude special item impairment charge gain sale genentech labcorp share vitamin case genentech legal settlement credit change accounting policy include continue business ie exclude fragrance flavours b ebitda earning interest financial income tax depreciation amortisation include impair ment correspond operating profit exclude depreciation amortisation impairment c dividend propose board director figure include special dividend relate spinoff fragrance flavours divisionletter chairman letter ceo board directors executive committee group performance glance division pharmaceutical diagnostic vitamin fine chemical roche group human resource annual report group account safety environmental protection roche holding ltd basel annual account table content finance financial review consolidated financial statement note consolidated financial statement report group auditor multiyear overview consolidated income statement adjust basis hold finance company roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor roche global market presence operating subsidiary associate company table content letter chairman group overall result good net income operating profit ebitda sale reach record high figure year low expect growth pharmaceu tical division prescription medicine diagnostic division contrast hold top previous high market share core business similarly vitamin fine chemical division reinforce global market leadership position continue face fierce competition letter chairmannet income increase year organisational measure deal reach remarkable total bil itparticularly key mar lion swiss francsa increase ketwe expect sale growth inoperate profit strong pharmaceutical division improve financial result major contribu second half tor impressive performance gain special itemsparticularly see number positive successful sale genentech share developmentstoday note major impact group satisfactionfor examplethat financial statement net income operating profit gross cash flow sale adjust basisconsolidate sale advance previous reach record high year billion swiss franc express local currenciessale merger boehringer mannheim grow diagnostic division far exceed expectation annual general meeting prove strategically important board director propose entire groupthe phar dividend increase maceutical division record swiss franc share non advance market segment vote equity securityif approve include consumer healthcareour thiswill fourteenth consecutive research development portfolio dividend increase form solid basis futurethe positive sale growth post genen challenging year history group guide employeesthank profession alism forwardlookingproactive commitment innovation innovation focusthey play pivotal role record performancei want express remain key success future sincere appreciation fortheir personal contribution tech mention group overall success majority interest lead biotechnology company con long string success tinue major strategic impor impressive standardssale tance future prescription medicine area special concern vitamins fine chemical divi note earlierprescription drug sale sion continue meet challenge weak expectedlagge intensely competitive market average market growth rate placesale volume increase negative impact price yearand division achieve addi roche securitieswe take tional cost saving intro development seriously duction improve production implement necessary strategic technology process letter chairman lastlyon june spin fragrances flavours division independent group operate givaudan namegivaudans share distribute special dividend holder roche share non thank fritz gerber voting equity security fritz gerber retire chairman board director roche holding ltd past decade annual general meeting april like pay tribute major progress goal man year roche major contribution rank industry leader group businessesbut guarantee future successwe fritz gerber chairman board director chief executive officer afford stand stillfor leave thank year instrumental dowe necessary building roche global leader farsighte timely action resource occasion help roche achieve extraordinary success prepare themthis involve question challenge future time ability welcome change oppor establish way thing tunity openness new idea prove decisive strength fritz gerber courage strike new realise essential group focus core directionsthese challenge requir competency take step necessary achieve focus skill e great deal personal initiative breadth vision great believer people keenly interested flexibility everyone staff development unwavere commitment innovation show chairmanship set example entire group recognise history group great potential biotechnology secure roche majority hold hasbeen guide commitment company genentech innovationand firmly convinced innovation remain key board director executive committee employee roche like toour success futurewe express deep appreciation fritz gerber recognition outstanding service devote energy continue board director decide appoint honorary chairman roche pathin year ahead aim remain member board director roche holding ltd delight achieve dynamic organic growth mr gerber retain close tie company fuel innovative product port folioanda pastwe remain open opportunity andre f leuenberger franz b humer strengthen position vicechairman board directors delegate board director acquisition diverse network alliance letter chairmanworke togetherfranz bhumer board director elect succeed chairman theexecutive committee employee build group future entrepreneurial courage vision energy fritz gerber letter chairman letter ceo roche look profitable net income rise billion swiss franc robust gain previous year adjust sale increase billion swiss franc operating profit include gain sale genentech stock billion swiss franc gross cash flow ebitda division show strong growth advance billion swiss franc financial income significant contributor group profitability increase strong billion swiss franc letter ceoour impressive earning growth show gain billion positive impact group swiss francsgrew roughly financial positionthe ratio equity rate sale minority interest asset increase year end hold expect pharmaceutical sale ing cash marketable security accelerate second half total nearly billion swiss franc portfolio include innovative reporting net debt bil product major therapeutic area lion swiss franc end wehave net creditor impressive earning growth positive impact net liquidity position billion swiss francswe use strong cash flow group financial condition year investment grow boehringer mannheim acquisition high net business strategically reinforce roche presence lead health liquidity position solid balance sheet care company net income increase year oncologyvirology trans adjust basisrising plantation medicinelast year billion swiss franc facilitate com acquire global right kytrila parisonsthese figure exclude special medicine oncologyin connec item include continue tion movewe sell north operationsanother good american marketing right coreg formance diagnostic division cardiovascularwe take record doubledigit gain stepbystep approach develop insale operate profitand market xenical exceptionally strong financial result major growth driversadjuste receive approval financial income increase european unionfour billion swiss francs united states japan new product indicationsaddi sale pharmaceutical tionallywe file regulatory division rise swiss franc term application key marketsinclude billionthey application pegasys hepati inlocal currenciesthis slowdown tiscother new drugssuch iban growth result loss market dronate osteoporosis hiv sharesale affect expiry fusion inhibitor tare advanced ofpatent coverage verseddormicum stage developmentin term anesthesia ticlid stroke quantity qualityour clinical united statesother factor include pipeline look promisingwith seasonally weak sale rocephin bac total project different terial infection flatten sale molecule developmentaddition xenical obesity follow extremely allywe improve position successful launch major market forfuture growth pursue active adjust operate profitwhich license policyin february letter ceo forexamplewe acquire innovative achieve costeffective treatment mentdevelopment work novel anticancer medicine latestage devel come address cause dis taqman analyser advanced opment osi pharmaceutical easeall roche diagnostic unit new generation labora produce pioneer research new tory system design routine anticipate sustained growth nextgeneration product pcrbase testing significantly fast consumer health businessafter strong competitor easiertaqman automate decline sale otc expect doubledigit sale growth step testing processfrom sample product rebound yeargrowing continue preparation detectionwe continue steadily expand range pcrbase test kit good performance diagnostic division record doubledigit gain sale operating profit roche molecular biochemicalsthe fourth diagnostic business major growth driver focus increasingly supply innovative system technology use local currency accuchek blood glucose meter pioneering field genomic billion swiss francsa tight focus market roche patient care proteomicsnow area intense global brand factor roche topselle product research activitythe late example contribute turnaround annual sale totalling rt world commercially billion swiss francsfollowe available system automate cellfree diagnostic division post successful integration ofavl medical protein synthesislaunche good result instrumentswe rt play major role background sluggish overall market leaderin fastgrowe pointofcare fastgrowe proteomic market growthwith sale advance segment hospital diagnostic billion swiss francsexpressed vitamin fine chemical local currenciesthis equivalent despite fierce market competitionwe division record volume increase increase resultwe anticipate positive future roche major product segmentsgaine gain additional market share laboratory systemsas continue market share background strengthen global leadership benefit launch additional intense competitionhoweverprice positiondivisional operating profit userfriendly analyser new test erosion sale medicinal million swiss franc reagent pursue effort cut feed additive business early rise sharplybooste cost raise productivity cause sale revenue decline division profit margin local currency bil centage point roche molecular diagnostic lion swiss francsas resultoperate amarket share profit million uncompromise focus cus undisputed leader continue swiss francsdespite improved produc tomer need aboveaverage sale record dynamic growthour test tivitywith new product come gain division business consider gold standard diag marketleadingedge competency unit contribute record result nose infectious diseasesdure research production prospect current year year sign licensing agreement expand global presenceparticularly excellentat stage health chiron corporation relate emerge market ofasia care delivery identify disease test hepatitis cthe agreement latin americawe ideally equip predisposition monitor treat mark end protract liti maintain leadership com ment response diagnostic tool gationha open way inten petitive global marketwe expect increasingly important factor sive development attractive seg positive sale growth letter ceoadditional lawsuit relate roche employee globe pricefixe agreement reveal remain key success factor vitamin industry futurei like addi settle indirect customer tional opportunity thank united statesthe formal investigation hard work valuable open mid european contribution build union progressadequate ing strengthen company provision togetherwe tackle challenge expenditure expect arise ahead roche track thevitamin case success position meet challenge aheadour strength include great financial flexi bilitya solid balance sheetthe pharmaceutical division strong pre ence hospital specialist seg mentsour strategic collaboration franz bhumer genentecha rich research devel opment pipelinethe turnaround roche consumer health global leadership diagnostic vitaminsas global pharmaceutical company world market leader diagnosticswe convince ideally equip benefit revolution take place genetic genomic proteomicswith use strong cash flow investment grow business strategically reinforce roche presence lead healthcare company broad implication medical science field interest diagnostic pharmaceutical con verge groundbreaking integrate healthcare solution drug tailor need specific patient population bear finallythe tremendous professional ism dedication nearly letter ceo board directors executive committee board director general meeting elect peter brabeck board director elect letmatheceo nestlto join franz bhumer new chairman board subject reelection board annual general meeting cantonal councillor kurt april dr humer assume jenny step board chairmanship april directors annual general continue serve chief meetingand charles weissmann executive officer available termin year board recognition major contribu man contribute greatly build tion rochethe board director e strengthen group name longstanding chairman businessesand extend fritz gerber honorary chairman sincere thanksthe board director boardhe continue serve propose businessman national board councillor walter frey john bell nuffield professor ofclinical werner stauffacher retire medicine oxford universitybe board director annual elect new member ofthe board general meetingfollowing appoint ment president ofthe swiss academy board committees medical scienceswe wish thank scope responsibility profstauffacher valuable con board director roche tribution group holding ltd delegate certain task year boardthe annual full attention chairman board directors executive committeeand vicechairman boardthe accounting system procedure executive committee audit committeethe finance organisation scope finan end henri bmeier investment committee com cial control retire roche chief financial offi pensation committee financial planningbudget bud cera position hold yearsthe execution board director wishes express chairman vicechairmen financial reporting shareholder deep appreciation dr meierwhose chairman vicechairman general public outstanding achievement board director serve jointly financial investment decisive factor group success nomination committeein continue serve member capacity prepare proposal committee approve capital expen boardanton affentranger board appointment diture divestment value name new chief financial new member concern million swiss franc officer succession planning evaluation candidate executive com confident new team board mittee directors executive committee ideally equip audit committee audit committee compose group track success exclusively board member fritz gerber chairman board director members executive com mittee compensation committee william mburn head committee assist board compensation committee pharmaceutical division january oversee management group compose board member franz bhumerwho head businessesparticularly respect member executive division end financial legal matter com committeeupon application concentrate overall group manage pliance internal business chairmanthe committee approve ment administrative policiesinclude poli group compensation policy cie safety environmental pro compensation receive member richard laubehead pharma tectionin particularthe committee executive committeegeneral ceutical division global consumer review scope extent exter manager major roche affiliate health businesshas appoint nal internal auditsthe indepen highlevel employeesin addi executive committeeeffective dence objectivity auditor tionit approve employee option pro january establishment appropriate gramme equity profit organisational structure safety sharing device define general environmental protection policy company pension benefit postemployment benefit finance investment committee plan finance investment committee assist board director issue relate financeinvestment capital asset evaluate risk areasspecificallythe committee review board directors executive committee board director january leave andre f leuenberger kurt jenny rolf hnggi andr hoffmann fritz gerber henri b meier franz b humer peter brabeckletmathe charles weissmann andrea oeri year birth term end board director dr hc fritz gerber chairman dr andre f leuenberger cid vicechairman rolf hnggi cid cid vicechairman dr franz b humer delegate peter brabeckletmathe cid andr hoffmann cid cid prof kurt jenny cid dr henri b meier dr andreas oeri cid prof charles weissmann cid secretary dr gottlieb keller board director franz b humer stand term board director fritz gerber retire chairman cid finance investment committee annual general meeting board director elect dr humer new chairman cid audit committee subject reelection board annual general meeting fritz gerber remain member cid compensation committee board retire chairman kurt jenny retire board director charles weissmann decline term january board annual general meeting board propose annual general meeting elect walter frey john bell board directors executive committeeexecutive committee january leave william burns jonathan knowles markus altwegg franz b humer richard laube heino von prondzynski daniel villiger anton affentranger year birth position executive committee dr franz b humer chief executive officer anton affentranger chief financial officer william burns pharmaceuticals division heino von prondzynski diagnostic division dr markus altwegg vitamin fine chemical division richard laube pharma consumer health prof jonathan knowle global pharmaceutical research dr daniel villiger corporate service secretary pierre jaccoud executive committee statutory auditor ernst young ltd roche holding ltd group auditor pricewaterhousecoopers ag january board directors executive committee group performance glance price development nonvoting equity security genussscheinin chf roche nonvoting equity security adjust swiss market index rebase help partly special gainsroche roche sale average double project expand market increase profitability enor digit growth past year ing distribution operation mously recent yearswhile continu rise period billion ing strengthen consolidated swiss francsnet income gross see anotherimpressive balance sheetsto facilitate compar cash flow ebitda climb improvement balance sheet ison mediumterm performance steadilyand exceed billion positionjust year changesthe figure present billion swiss francsrespectively boehringer mannheim acquisition exclude special item timein order remain roche net creditorwith refer solely ongoing operation astrong innovator net liquidity position billion spunoff fragrance flavour world lead healthcare group swiss francsthe ratio equity business exclude major marketswe consistently minority interest total asset rise high cash inflow invest percentage point ment research development avery solid group performance glancesale divisionin millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour group figure net income millions chf net income share ebitda millions chf nonvoting equity security chf operating profit million chf research development millions chf addition property plant equipment million chf special charge figure adjust basis figure fully comparable previous year givaudan spinoff genentech transaction accounting policy change group performance glance latot latot latot latot latot roche develop diagnostic test promote effective individualised care cancer patient test possible predict probability clinical benefit particular treatment monitor patient response medicine like xeloda herceptin elsa k treat colorectal cancer xeloda anticancer drug inactive reach tumour tissue drug good tolerability profile improve elsas quality life xeloda tablet form home time spend grandchildrenpharmaceutical division brief million chf change sale rx genentech otc ebitda operating profit rd expenditure employee adjust basis pharmaceutical pharmaceutical business account twothird group sale post increase sale revenue operating profit sale prescription medicine grow fast market average achieve significant milestone number major therapeutic area particularly oncology transplantation virology sale biotechnology company genentech hold majority interest close collaborative relationship continue outperform market non prescription medicine sector roche consumer health record substantial rise sale show growth track roche submit marketing application new chemical entity supplemental indication late year acquire global right kytril drug chemotherapy pharmaceutical operating profit reach million swiss francswith operating margin ofthe division ebitda total million swiss francsor sale focus pharmaceutical business therapeutic area significant unmet medical need special expertise experiencein achieve fur ther significant advance area oncology leadership build inno vation continue reinforce strong presence oncologyamong factor contribute average growth potential market major advance early diagnosisbetter target therapy base identification cancer sub type rapid acceptance innova tive new product sale xelodaa novel tumourselec confident ability launch tive cancer drug oral usegrew bymore million major new product additional indication swissfrancsxeloda monotherapy year ensure continued growth approve country metastatic breast cancer resistant pharmaceutical division come year certain standard chemotherapiesthis franz b humer ceo head pharmaceutical division december product file breast cancer treatment japan study result publish late year prescription medicine global show xeloda docetaxel presence key therapeutic area chemotherapy combination reinforce sale pharmaceutical produce superior survival metastatic division rise local curren breast cancer patient compare cie million swiss franc withmonotherapyxeloda prescription drug sale include approve firstline treatment genentech increase million metastatic colorectal cancer europe swiss francsfor yearonyear growth food drug administration rate swiss franc fda issue letter approva local currencieson adjust basis bility drug indication pharmaceuticalsa total medicine sale half billion swiss franc division product roaccutan mabthera cellcept neo jointly market roche genentech recormon herceptin viracept post dou include supplemental indication update mid bledigit sale growth local currency xenical february consolidated position lead pharmaceu jointly develop roche gilead science tical weight loss weight management topselle prescription product include genentech product generic indication sale millions chf rocephin ceftriaxone bacterial infection roaccutanaccutane isotretinoin severe recalcitrant nodular acne xenical orlistat weight loss weight management mabtherarituxan rituximab lowgrade nonhodgkin lymphoma cellcept mycophenolate mofetil transplantation prevention acute rejection neorecormon epoetin beta anemia herceptin trastuzumab metastatic breast cancer viracept nelfinavir mesylate hiv infection dormicumverse midazolam anesthesia sedation nutropinprotropin somatropinsomatrem growth hormone furtulon doxifluridine cancer colon breast stomach activase alteplase myocardial infarction neupogen filgrastim gcsf neutropenia pulmozyme dornase alfa dnase cystic fibrosis lexotan bromazepam anxiety tension state invirasefortovase saquinavir hiv infection rocaltrol calcitriol osteoporosis roferona interferon alfaa hepatitis b c cancer madopar levodopa benserazide parkinson disease dilatrend carvedilol heart failure hypertension angina pectoris torem torasemide hypertension cymevenecytovene ganciclovir cytomegalovirus infection rivotril clonazepam epilepsy major product approval launch product generic indication country cellcept mycophenolate mofetil prevention acute rejection pediatric kidney transplantation usa prevention acute rejection liver transplantation eu switzerland usa herceptin trastuzumab metastatic breast cancer eu roferona ribavirin interferon alfaa chronic hepatitis c eu tamiflu oseltamivir treatment influenza b canada japan latin america prevention influenza b usa treatment influenza b child age year old usa xenical orlistat weight loss weight management australia china xeloda capecitabine metastatic colorectal cancer australia canada eu switzerland pharmaceuticals herceptin sale sharply facilitate development combina advance tion regimen include herceptin million swiss francsherceptin breast cancer drug selec mabtherarituxanthe humanise tively target receptorthus monoclonal antibody approve blocking signal pathway cause cancer treatmentlikewise continue uncontrolled cell growthroche intro strong growthas sale climb duced herceptin europe million swiss prescription produtcs include genentech metabolic disorder japan dermatology latin america central nervous system oncology sale region sale therapeutic area infectious disease north america europe cardiovascular disease virology inflammatory autoimmune disease francsthis product indicate total sale division million chf certain form ofnonhodgkin lymphoma nhla cancer ofthe lymphatic systemroche hold world wide marketing right mabthera outside united states co market drug japanuse monotherapy combination chemotherapymabtherarituxan highly effective tolerate patientsourobjective register thedrug firstline use lowgrade nhland inautoimmune disease marketing application area inwhich mabtherarituxan submit year japan potential revolutionise treatment genentech market breakthrough treatment united stateswhile bondronata thirdgeneration bisphos roche hold exclusive marketing right phonate bisphosphonate countriesseveral large available intravenous oral scale study currently evaluate formulation management additional indicationsduring year hypercalcemia malignancyexperi enter research alliance ence strong demandin oral bristolmyer squibb aventis form bondronat submit pharmaceutical approval metastatic bone disease medicineafter strong start sale duration severity flu breast cancer patient level offand plan decrease risk complication develop return growthkey activ product available influenza sale neorecormon rise itie include programme inform treatment united statesjapan strongly mainly patient health benefit oflo canadaswitzerland coun development new market segment ing weighteducate right try southern hemispherethe oncology dialysisa marketing way use xenical achieve longterm additional datum request filing application use hematological weight control provide support eu regulatory authority cancer file european encouragement therapyother submit february union july initiative aim realise application additional indica drug largely untapped potential vari tionsin united states tamiflu december roche strength ous patient population example wasapprove influenza prevention ene oncology portfolio acquir overweight man address weight adult adolescent aged year e global right antinausea relate risk factor patient type old treatment drug kytril smithkline beecham diabetesdyslipidemia hyperten influenza child age year kytril give cancer patient sionrecent study show xenical old suppress severe debilitate lead significant weight loss nausea vomiting associate improve weight control patient chemotherapy type diabetesallowe patient reduce dose ofglucoselowere early roche genentech medicationroche launch clinical sign agreement osi phar development programme aim maceutical new york co extend use xenical development commercialisation conditionsresearch continue charac novel anticancer drugthe drug terise secondgeneration lipase inhibi know osiis currently torandotherapproachestowardsobesity phase ii clinical trial lunghead neck ovarian cancer research development marketing team work closely make expand number position weight managementxenical estab sure medicine optimally serve doctor lishe itselfas world lead pre patient need able fully scription pharmaceutical weight loss weight managementit realise product potential future commercially available weight loss product act locally gastro william burns head pharmaceutical division january intestinal tractwhere reduce absorp tion ofdietary fat virology major growth opportuni roche nextgeneration interferon product roll year tie virology segmentroche pegasyswas submit review inaustralia indonesia score major success tamiflu fda united states receive marketing authorisation oral neuraminidase inhibitor treatment hepatitis eu appli chinakorea taiwannow year market cation file february xenical successfully launch lead influenza medicine twolargescale clinical trial compar inmajor countrieswe want steadily tamiflu prevent influenza virus ing pegasys standard interferon develop market novel replicatingthus reduce therapy show pegasy provide pharmaceutical statistically superior efficacy inhepati schedule ofviracept feel tis cpegasys currently theonly advantage patient pegylate interferon show tobe safe effective hepatitis c patient sale aid medicine invirase suffer liver cirrhosis fortovase decline result hepatitis c increasingly recognise increasingly competitive market major cause liver disease fortovase continue deliver liver failuremore million therapeutic potential saquinavir people worldwide infect andused combination ritona lifethreatening virus virha maintain leadership pretreate patientsvery promise hiv areaviracept sale con new datum support use forto tinue solid growth trenddata vase dailylowdose ritonavir clinical trial show present conference patient receive viracept remain retroviruse opportunistic infec therapy significantly long tion february experience few effect take protease united states submit inhibitorthe twice daily dose new drug application valcyt treatment cytomegalovirus retinitis patient aid integrate health care solution gain momentum integrate health care solution ihcs programme offer opportunity progress develop improvehealthcare delivery combine innovative diagnostic test treatment e entirely new class antihiv forpatient open way individualised care goal develop medicine know fusion inhibitor product service improve treatment outcome medicine prevent hiv penetrate enable health professional timely diagnosis predict probability infect host cellsthe fusion clinicalbenefitand monitor treatment response inhibitor enter phase iii clinical trial phase ii testing initial trial novel diagnostic test early detection heart failure look start promise test run elecsys analyser launch second half timely diagnosis heart problem improve chance successful transplantation medicine building treatment cardiovascular medicine like dilatrend torem ona position strengthcellcepta potent immunosuppressant pre oncology score major technology breakthrough assay capable vent kidneyheart liver transplant ofanalysing paraffinembedde tissue sensitive polymerase chain reaction rejectioncontinue strong pcr method tissue sample diagnose cancer normally preserve growththe product approve paraffin near future lead new test cancer overexpress use liver transplantation protein anticancer medicine herceptin currently offer highly target united statesthe european union therapy herpositive breast cancer new possibility open switzerlandin december cellcept measure enzyme level tumour important parameter effective use receive regulatory clearance anticancer medicine xeloda clinical trial currently way validate specific foruse pediatric kidney transplant biomarker design facilitate patient selection substantially increase recipientsadditional datum con response rate drug expect allow xeloda therapy target firmed lowtoxicity immuno evenmore effectively patient breast colorectal cancer suppressive regimen combine pharmaceuticalscellcept zenapax significantly expectedsale dormicum improve patientsquality oflifeour verseda drug hospital commitment transplantation medicine anesthesia sedationfell nearly include major funding million swiss franc roche organ transplantation research dueto patent expiry united foundationan organisation pro state mid motes clinical transplantation research sale carvedilol dilatrendkredex wellestablishe product ane coreguse treat hypertension thesia infection severe acne angina pectoris chronic heart cardiovascular disease roaccutan failurerose markedly spur accutane post doubledigit sale new datum major international growthhelpe particularly clinical study show significant positive sale trend north america survival benefit patient severe oral retinoid vitamin derivative chronic heart failureexclusive right highly effective treatment severe coreg north america sell nodular acnemarketing application smithkline beecham december new formulation file dur smithkline beecham roche pre ing year united states viously copromote product canadain additionwe institute united stateswe remain supplier measure defend product effectivesafe welltolerate possible entry generic medicine country competitor market second half range roche consumer health focus service provide prescriber strong brand sale roche patient optimise treatment consumer healthour otc medicine roaccutanaccutane recently businessrose million expand furtherin united ve return growth otc sector statesfor examplethe comprehensive pregnancy prevention programme concentrate effort build core forpatient take drug strengthen effort prevent global brand fetal exposure potent retinoid richard laube head roche consumer health antibiotic rocephin remained topselle medicinewith sale focus otc brand millions chf total billion swiss franc product use sale outpatient parenteral antibiotic aleve analgesic therapy rocephin continued supradyn multivitamin increaseuse drug outpatient bepanthen skin care setting establish rennie antacid united statescanadaitalythe redoxon vitamin c united kingdomargentina mex berocca multivitamin icoand introduce saridon analgesic chinajapan central america elevit pronatal multivitamin pharmaceutical swiss francsin local currency term sale growth strong north clinical oncology meeting sale significant americawhere aleve sale rise genentech announce encourag turnaround previous year sharplyand europewhere roche e preliminary finding decline sale wasdue primarily consumer health rank second phase ii trial evaluate antivegfa restructuring activity commence theotc marketin latin america monoclonal antibody starve tight focus key particularly mexicosale grow tumour blood supplythereby global brand fasterthan market thank highly inhibit tumour growthroche focus marketing option codevelop comarket compoundphase iii trial consumer selfmedication currently way assess safety efficacy antivegf colo rectalnonsmall cell lung breast cancer see approval skin hair care launch genentech tnkasethe analgesic gastrointestinal product drug currently investigation clinical trial design evaluate sale therapeutic area cold remedy heart attack treatment regi men combine tnkase vitamin agent research productivity enhance boost productivity set new core brand account genentech outperform mar standard recently imple half total consumer health sale ket new cancer therapy mente variety strategy includ sale brand increase year close working relation ing initiative drug optimisation year swiss franc ship genentech new lead chemistry creation local currenciesaleve increasingly important global research informatic system sell productthank healthy sale scientific commercial point improve productivity growth exist marketsparticularly viewand continue extremely search safeeffective medicine united statesand rollouts new successfulroche hold majority flexibleharmonise procedure marketssale supradynroche interest californiabase establish research site consumer health second strong biotechnology company reduce time resource require brandalso show doubledigit gain genentech sale united place compound lifecycle entry new marketsnotably state dol teamsin number new spainand product relaunch lar billion swiss franc research compound go theunite kingdom drive growth critical preclinical evaluation process supradyn new formulation genentech focus research total seven new molecular tailor specifically need development effort heart disease entity clear clinical test consumer successfully cancerthe number number ingeighteen new drug compound launch number european killer disease united states expect enter preclinical develop marketsall core otc brand market anticancer prod ment end indica post healthy growthlargely uct seven oncology project tion range obesitydepression aresult improve marketing activ pipelinegenentech position alzheimer disease oncology itie particularly area direct play active fight osteoporosis hiv toconsumer communication cancerat american society pharmaceuticalsnew business model basilea phar pharmaceutical businessproteomic maceutica continue lead increase number strategy focus core disease potential target molecule provide area spin drug additional stimulus discov discovery activity new biotech ery new therapeutic compound startupcalle basilea pharmaceutica objective roche pro follow early spinout result teomic research diagnostic creation biotech identify protein startupsnovuspharma italy new marker preclinical clinical actelion switzerlanda result test cancermetabolic disorder roche rd knowhow decade inflammatory disease cardiovas accumulate intellectual property relate antibioticsantifungal dermatology integrate metabolic disease virology broadly base biotechnology com vascular disease panyroche retain minority oncology interest basilea pharmaceuticawith research project genitourinary disease major therapeutic area option acquire global develop inflammatory disease ment marketing right select central nervous system compound genomics genetics proteomics forbetter healthcare solution pharmaceutical research centre progress decipher human genome provide scientist basel switzerland metabolic disorder wealth ofinformationbut stilla central nervous system great deal ofwork identify vascular disease key genetic variation kamakura japan oncology people susceptible particular nutley new jersey usa metabolic disorder diseasesat roche strive oncology support effortswhich vascular disease decide step involvement palo alto california usa central nervous system genetic genomic redirect inflammationbone disease focus ofresearch basel insti genitourinary disease tute immunologyestablishe penzberg germany oncology year agothe institute trans welwyn garden city uk virology form centre medical geno roche center medical genomics mics associated basel switzerland basic research geneticsgenomic group global research organisation year roche pharmaceutical diagnostic division invest roughly mil lion swiss franc strengthen group proteomic researchin pharmaceutical currently project total different molecule clinical development theseproject generate stream new product ensure future growth balanced product pipeline product indication phase bondronat oral ibandronate treatment bone metastasis breast cancer patient iii antivegf type solid tumour combination chemotherapy iii neorecormon epoetin beta anemia hematologic malignancy nda file herceptin trastuzumab adjuvant therapy breast cancer iii mabtherarituxan rituximab intermediatehighgrade nonhodgkin lymphoma combination chemotherapy iii xeloda capecitabine combination therapy breast cancer iii fusion inhibitor hiv infection iii viracept nelfinavir mesylate new formulation hiv infection iii valcyt oral valganciclovir prevention cytomegalovirus disease solid organ transplantation iii valcyt oral valganciclovir treatment cytomegalovirus disease aids nda file pegasys pegylate interferon alfaa chronic hepatitis c nda file pegasys pegylate interferon alfaa combine ribavirin chronic hepatitis c iii pegasys pegylate interferon alfaa hivhepatitis c coinfection iii oral ibandronate prevention treatment postmenopausal osteoporosis iii anticda monoclonal antibody hu moderatesevere psoriasis iii roaccutanaccutane isotretinoin new formulation severenodular acne nda file xenical orlistat treatment prevention type diabete iii xenical orlistat weight loss weight management child iii dilatrend carvedilol severe chronic heart failure iii dilatrend carvedilol postmyocardial infarction iii activase alteplase catheter clearance nda file xolair omalizumab allergic asthma seasonal allergic rhinitis nda file tnkase tenecteplase iiaiiiacombination acute myocardial infarction iii nda new drug application genentech compound optin candidate forroche genentech compound develop andor market roche jointly develop roche trimeris jointly develop genentech xoma genentech project jointly develop genentech tanox andnovartis study conduct cor therapeutic scheringplough merck aventis pharmaceuticalsby combine strong inhouse rd focus seven broad range market product wellbalance rd key therapeutic area successful strategic alliance pipelinewe equipped significant investment new technology achieve strong organic growth year aheadat time ensure steady stream new drug candidate remain open opportunity future licensing agreementsacquisition alliance help reinforce jonathan knowles head global pharmaceutical research ourposition pharmaceutical industry cular diseasesuch marker yield outlook equipped important information course successful future expect sale major global pharmaceutical com disease efficacy growth pharmaceutical divi pany world leader invitro thedrug treat sion accelerate diagnosticswe unique position recently launch product benefit emerge revolu invest future roche tamifluxenicalmabtherarituxan tion medicine exploit syner invest billion swiss franc herceptin xeloda impor gy application cut pharmaceutical rd alonea tant growth driversa newly edge science complementary increase previous yearaddi acquire kytril wellestablishe business tional research building product cellcept neo operational year recormonin additionwe file research centre penzberg germany approval pegasys united basel switzerlandrepresenting state europeand thedevelop investment million ment new drug ibandronate swiss franc sitethese new hiv fusion inhibitor facility improve latestage clinical testing efficiency research anddevel progressing opment effort united states remain world alliance decode genetics important pharmaceutical mar iceland comprehensive ketwhich intend expand cluster important collaboration presence futurein bioscience company univer expect additional sale sitie produce important generate bythe rollout new result include productspegasys valcytand identification gene link acquisition kytril expand schizophreniaproviding labelling xenical manage genetic target development ment type diabetesa major new new diagnostic therapeutic indicationtheupcoming launch approach diseasein addition xeloda europe continue gene location identify growth otc brand risk factor cause contrib expect helpstrengthen ute strokealzheimer disease pharmaceutical business osteoporosis peripheral arterial occlusive disease pharmaceutical grow number people infect hepatitis c virus highly sensitive extremely reliable amplicor hcv test enable physician like dr k ofaachen germany detect infection virus early monitor patient response treatment number international programme underway roche develop optimal diagnostictherapeutic combination viral disease example currently work improve diagnostic tool assist interferon treatment hepatitis cdiagnostic division brief million chf change sale patient care laboratory system molecular system molecular biochemical ebitda operating profit rd expenditure employee adjust basis diagnostic diagnostic division maintain strong growth previous year background sluggish expansion global invitro diagnostic market market share gain yearonyear increase operate profit margin enable extend global market leadership sustain dynamic growth molecular diagnostic exceptionally good result diabete monitor product main contributor strong performance success ful integration avl medical instrument market leader rapidly grow hospital emergency diagnostic market explosion knowledge result mapping human genome open exciting possibility new diag nostic product growth diagnostic ebitda rise million swiss francsa systematic focus customer need aboveaverage sale gain business seg ment contribute record result patient care impressive progress diabete monitor emergency diagnostic roche patient caresup plier world lead product people diabete innova tive pointofcare diagnostic testscon tinued successful track record previous yearsparticularly dia bete blood glucose monitor sec torwith sale billion swiss franc globally market accuchek line product blood glucose monitor roche group topselle brandtotal sale roche patient care inlocal currency againthe accuchek advan tagecomfort strip blood glucose meter major driver sale growth global market technology leader human diabete monitor businessat end roche launch accu diagnostic roche superbly place translate chek compactthe world fully result genomic proteomic research test automatic blood glucose metermuch simple use test strip meet specific need insert cartridge automatically heino von prondzynski head diagnostic division prepare position excep tionally accurateitoffer significant improvement forpatient market leadership extend slowgrowe market roche consoli clinical test carry dated lead position major point care increa segment thank innovative business ingly important worldwide mean model efficient marketingsale make healthcare delivery diagnostic division advance efficient control coststhe local currency acquisition ofaustriabase avl med million swiss francsoperate ical instrument roche graz profit million substantially expand product swissfrancsand division portfolio highpotential hospital diagnosticspointofcare segment rapid diagnosis moderate market growthincreasingly emergency intensive care hospital highvolume clinical medicine time laboratory ask integrate roche market leader area highthroughput system improve costefficiencyby respond major new product launch new requirement automate pointofcare segment include car pre postanalysis processingan diac ddimer opti rcardiac expand range test menus ddimer new assay allow doc innovative developmentswe tor rule pulmonary embolism enhance strong deep vein thrombosis rapidly market position reliablyit roche cardiac readera prove instrument clinical chemistry segment diagnose damage heart muscle thenew cobas integra analyser opti ra blood gas analyser devel launch end opedby avl medical instrument thank outstanding userfriend employ reusable test cassette simplify decentralise testing oper total sale division million chf ate room environmen tally friendly economical optimal userfriendliness key objective research dia bete care segmentamong thingswe develop system require small blood sample combine sample blood glucose determination single stepa long term goal development sys tem enable noninvasive liness highprecisionthe new blood glucose measurementwithout system establish need bloodsamplingin market quickly small hospital pointofcare segment integra demand effort focus develop remain strong second year highly integrate diagnostic system launch despite tough competition emergency intensive care market response highvolume department laboratory segment modular analyticsan individually configurable laboratory system grow trend highthroughput system combine costeffective analyser roche clinical chemistry immunodiag laboratory systemsthe world lead nosticswasvery positive supplier integrate analytical sys tem clinical laboratoriesposted sale elecsys analysersfor het sale gain local currency erogeneous immunoassaysonce amid fierce competition show aboveaverage growthin diagnostic hematology cooperation put market leader gene amplifica japanese company sysmex ex tionbase molecular diagnosticsthis tend additional marketsroche reflect yearssustaine rapid hold market share coagulation growthwhich continue automate urinalysis segment impressive local currency increasethese gain result work research facility strong demand product base cooperation japanese highly sensitive polymerase partnerhitachiroche laboratory chain reaction pcr techniquepcr system pursue project consol enable direct detection pathogen asiapacific south america molecular biochemical molecular system sale region sale business unit north america europe africa patient care laboratory system idate range analytical system individual genetic variation common platformthis involve minute quantity sample material harmonisation consolidation technology single work test detection ofaid station integration sample han hepatitis infectious disease dle datum managementpermitting regard gold standard allinone solution indi molecular diagnostic continue vidually configure line cus rank topselle product tomersneedswe work despite strong competitionamplicor expand assay menus elecsys hiv monitorwhich measure hiv linefocuse initially test concentration bloodremaine infectiousdiseasesthe main objective far frequently quantita joint proteomic research initia tive aid testtest sexually trans tivewith pharmaceuticals division mitte disease screen blood p development new productsboth segment potential diagnostic marker type developmentposte cancermetabolic inflammatory average growth disorder cardiovascular disease marketing application file molecular system expand united states pcrbase test gold standard new segment monitor aid treatmentboth market share successfully launch roche molecular system undis marketstwo qualitative hepatitis c diagnosticsdiagnostic division research lab patient molecular biochemical molecular system reagent system gene analysis biomedical pcrbase assays automate analyser detect research investigate cause predisposition infectious disease cancer cardiovascular disease specialty biochemical industry hereditary disorder monitor treatment investi gate genetic cause disease reagent molecular cell biology lightcycler amplicor test cobas amplicor ampliscreen ampliprep lumiimager magna pure lc rts patient care laboratory system diagnostic product pointofcare testing patient integrate analytical system clinical laboratory selfmonitore blood glucose meter accom complete solution immunodiagnostic work area panye datum management software system coagula laboratory network solution reagent clinical chemistry tion monitor blood gas analysis electrolyte determi immunodiagnostic product coagulation testing nation urine test strip rapid drugsofabuse screen hematology automate urinalysis test accuchek softclix camit cardiac reader opti omni cobas integra rochehitachi cobas core elecsys stago molecular system molecular system reflotron comburtest coaguchek ontrak sysmex miditron supertron testswere submit fda pcr marketto secure roche objective translating result accord fasttrack review molecular systemslongterm success human genome project status decide invest new diagnostic product individually stateoftheart production facility tailor healthcare solution licensing agreement conclude new jersey entire range usbase chiron corporation cover pcrtest molecular biochemical fore hiv hepatitis c patent right genomic proteomic mark end protract litigation cobas taqmana nextgeneration sale roche molecular biochemi set stage additional analyser speed simplify calswhich manufacture reagent future growthin additionin mid routine pcrbase testing high system industrial biomedical sign agreement throughput environmentsis researchwere local curren company applera allow advanced developmentwe ciesdriven mainly dynamic growth roche applera develop step rd activity german marketsmarket market product pcrbase aim significantly expand share gain united states applicationswe expect range pcr testsroche molecular particularly strong enhance potential growth system vigorously pursue diagnostic good result primarily roche molecular biochemical sale roche innovative lightcycler continue successful transforma systemlaunche year ago tion reagent manufacturer far exceed expectation developer supplier innovative lightcycler employ principally system breakthrough field ingenetic research diagnostic genomic proteomicsof particu pcrbase amplification genetic lar significance launch materialthis product line ex rt world pande end automate system cellfree protein launch magna pure lca module expressionuntil expression offer fully automate nucleic protein code particular gene acid isolation sample important research material realtime detection cause disease lightcycler areasha difficultthe require protein frequently syn thesise quickly sufficient quantitiesthe new rts fore play major role rapidly develop proteomic market integrate healthcare benefit patient collaboration virology pharmaceutical diagnostic division agreement sign early continue produce excellent result marketplace prionicsa swiss biotech companywe handle worldwide stateoftheart treatment algorithm define hiv distribution screening test comprehensive programme viral load monitor viral resistance genotype cattle disease bsethe testwhich therapeutic drug level monitor combine use retrogram decision support wasdevelope prionicsis software analyse result help physician choose antihiv drug use european countriesthe combination high probability success promote effective use agreement provide forcollabora roche medicine hiv viracept invirasefortovase tion develop test detect bse live animal influenza programme mark real breakthrough early detection treatment joint development diagnostic test common viral illness combine use realflu surveillance system rapid creutzfeldtjakob disease man influenza test innovative drug tamiflu ensure targeted effective influenza therapy additional strategy tool develop improve detection moni unit research effort continue tore local influenza outbreak diagnosis treatment effective focus develop new application pcrbase diagnosticsespecially clinical trial pegasys hepatitis c amplicor hcv monitor show field oncologyinflammatory areliable mean assess clinical benefit month therapy mean disease cytologyanother key treatment review early patient predict probability response areais gene function analysisa logical limited continue great potential therapeutic benefit patient extension human genome showing response project undertaking havebeen unthinkable major roche research site equip resource identify inte high throughput automation grated healthcare opportunity early stage drug discovery development possible pcr technologyroche exploit improve treatment outcome molecular biochemicalsrapidly evolv diagnosticse strategic role engine set continue pioneer innovation division reflect scientific work fieldone trend work contact forefront expect stimulate additional sale new development area segment rise demand diagnostic product screen donate blood derivativesroche highly optimally position continue accurate pcr test dynamic growth diagnostic test substantial proportion division business unit blood plasma productsour new excellent basis growth ampliprep system pcr sample preparationschedule launch roche patient care enormous soonbring close objective growth potentialfuelle mainly fully automate pcr testing rapidly expand diabetes marketin hospital pointofcare segment immensely promising field expand product portfolio know genomics proteomic fact roche con main focus roche molecular bio trol entire value chainfrom rd chemicalswhose objective right sale marketing translate research finding significant advantageroche product routine diagnosis patient care expand product range launch overallwe intend step innovative blood gas elec research effortswith clear focus trolyte analyser highgrowth marketsour activity direct create new launch additional userfriendly market generate additional instrumentsexpande assay menus business new service exam costcontrol productivity pledeveloping solution enable measure positive impact network datum generate roche laboratory systemsperfor different location hospital mance highly competitive business laboratoryat patient bedside environmentin immunochemistrythe etcour longterm priority launch elecsys e module thecreation intelligentuserfriendly schedule early con system service tribute sustain aboveaverage growththe new module enhance exist system platform combine preanalyticsclinical chemistry immunodiagnostic single work station worldwide growth knowledge genetic basis disease open range new business opportuni tie roche molecular system diagnostic vitamin play crucial role balanced nutrition number factor fromphysical exertion emotional stress smoke illness pregnancy increase person vitamin requirement roche vitamin add multitude food product beverage vitamin receive attention today fromthepublic large researcher roche consumer health aunit pharmaceutical division lead supplier vitamin product broad range brand thatincludes supradyn berocca redoxon elevitvitamin fine chemical division brief million chf change sale vitamin carotenoid fine chemical ebitda operating profit rd expenditure employee adjust basis vitamin fine chemical vitamin fine chemical division record significant volume growth major product segment divestment medicinal feed additive business continue downward pressure price lead decline value sale result operating profit despite efficiency gain rigorous focus cost expand lead market position help new product launch uncompromise focus need key global account investment modern manufacturing process aim raise productivity important milestone mark completion new production facility biotin vitamin b grenzach germany formulation vitamin carotenoids sisseln switzerlandthese capital investment systematic effort upgrade division plant late technological standard optimise manufacturing capacity consolidate production key vitamin suitable site worldwide vitamin fine chemical medicinal feed additivessale revenue advance swiss francsthe impact pricing pressure margin partially offset increase sale volume improvement operational efficiencyas result operating profit ebitdadecline million million swiss franc respectivelythese figure equivalent sale global demand vitaminscarot enoid citric acid remain theincrease ourvolume sale expand signifi cantly fast marketwith doubledigit growth record astaxanthinvitamin b pantothenate biotincitric acidpolyunsaturated fatty acid feed enzymeswe score particularly strong market share gain highly competitive citric acid market production capacity citric acid plant tienen bel gium wuxi china expand year move reinforce thank economical highquality product position world lead supplier segment food pharmaceutical cosmetic feed industry ideally equip continue expand competitive pressure mount pro ducer continue consolidateby market leadership contrastthe price key vita markus altwegg head vitamin fine chemical division minsinclude vitamin ec b stabilise second half slip early yearin case biotinprice rise mod good performance challenge estly response strong market marketplace sale vitamin demand fine chemical division slightly yeardecline follow sale medicinal local currency million feed additive business alpharma swiss francsas result price erosion focus resource divestment medicinal ourcore business vitamin feed additive businesscomplete carotenoid fine chemical early exclude sale vitamin today account roughly vitamin fine chemicalsonehalf divisional salesin promise growth sector countriesand contribute attention centre particularly need major industrial customer appreciably good sale growth rollout new product lutein thingsthis involve product categoryto enable carotenoid helps maintain eye organisational change allow serve animal nutrition industry healthand highly standardise natural support customer effec well futureconstruction source vitamin eand phytasea feed tively develop tailormade prod begin vitamin premix plant enzyme codevelope novozyme uct market pet food deinze belgiumand increase bioavailability decision build additional phosphorous animal feedsthus pivotal role animal nutrition sale feed premix facility spainhun reduce environmental impact carotenoid animal nutrition garykorea vietnam cost animal productionwe industrythe division large market asiapacific food industry cosmetic pharmaceutical sale region sale customer segment north south america europe africa animal feed launch vitamin b manufacture total sale division millions chf fermentationwhich supply significantly improve product form use animal feedsfood pharmaceutical start growth strategy augment strategic alliance novozyme aim develop major new feed enzyme adjust basis product benefit livestock health environmentin market roche sell product cover alliance segmentwere exceptionally goodthis key supplier food phar primarily continue strong maceutical industry sale tailor product customer demand astaxanthin aqua foodprocesse industry need roche supply broad range culture sector norway chile substantially volume termshelpe product contribute significantly canthaxanthin canadabiotin grow trend fortify staple improve nutrition healthour sale upfuelled nutrient food vitaminsdemand main customer producer pro important role maintain health functional food stimulate cesse foodsanimal feedspharmaceu performance livestock pet increase consumer awareness tical cosmeticsin new phytaseronozyme pwa importance certain nutrient tight operational focus approve marketing number healthby contrastsale phar vitamin fine chemical maceutical industry fall slightlylargely life expectancie alter people weak demand idea attitude nutrition dietary supplement sectorwe open significant market expand global network opportunitieswe specialise premix plant serve step search active com food pharmaceutical industry ponent natural product order strengthen position show beneficial effect lead supplier vitamin onhuman healthour development segmentsa new facility complete pipeline include product help el salto mexicoand additional prevent osteoporosislower cholesterol plant supply industry prevent cardiovascular disease build south africa china improve cognitive functionzeaxan thina close relative betacaroteneis volume sale rise cosmet ready market ic segmentthank particularly launch complement lutein brisk demand vitaminsthe market zeaxanthin help protect vision sunscreen continue expand reduce risk agerelate eye consumer increasingly aware disease macular degeneration importance protect skin ultraviolet ultraviolet supply market b lightsales ultraviolet sun expand range new product screen parsol heavily disease prevention divi affect loss patent protec sion prime goalshere effort tion europe willbenefit science deep understand role sound research development identi nutrition healthadvance fye exploit new market area facilitate use opportunity research develop late technology molecular ment activity focus optimise geneticsa field roche manufacturing process term leaderthese technology finally qualityproductivity environ make possible identify mental performance develop underlying cause degenerative new product customer disease develop innovative segment serve approach combat develop innovative product formu investment target maintain lation division core cost leadership investment prop competenciesnewhigherdose vita ertyplant equipment total min formulascombination vita million swiss franc com min new betacarotene pare million swiss franc product develop meet theprevious year customersneed well systematic effort optimise capacity divisional production facility trend functional food worldwide concentrate manufac illustrateslifestyle change long ture good locationsthe aim vitamin fine chemicalsisto achieve substantial additional task force sight life saving reinforce position year roche actively engage fight vitamin deficiency lowestcost supplier key child develop world found task force sight product life provide vitamin free charge nutrition intervention programme fund research project share technical knowhow sight life important milestone realising involve nearly project large small africa asia latin america strategy completion new activity include distribution roughly million free vitamin capsule sup production facility biotin port training programme health worker vitamin fine vitamin b grenzach germany chemical division sight life support programme promote represent investment tification staple food inception task force receive million year roughly million swissfranc fund roche deutschmarksin dalry scotland expand capacity upgrade vitamin c manufacturing process customer new growth opportuni cost million pound ster tie establish core business lingthe phase construction vitaminscarotenoid fine chemi complete spring calswe expect continue strong startup new facility carotenoid demand productsparticularly vitamin powder formulation aquaculture functional food sisseln switzerland establish segmentsnewly launch product site divisional centre excel naturalsource vitamin e lence powder manufacture tech lutein new feed enzymewill nologysisseln site stimulate additional sale growth new vitamin e plant annual capacity tonnesthe facility onehalf research development complete year expenditure allocate maintain cost approximately million swiss expand cost leadership vita franc min production long term year want october open cut cost manufacturing world large vitamin b factorie main product half help shanghaiin line strategic aim radically new production technology expand division chi programme introduce year nese manufacturing baseadditionally regional marketing organ new citric acid plant build isation efficient help wuxiit begin manufacture achieve profitability target china domestic market competitive edge research export second quarter production knowhow expand global presenceparticularly solid basis profitable growth emerge market ofasia vitamin fine chemical division latin americawe ideally equip continue strengthen opera maintain leadership com tional structureswe streamline petitive attractive global market product portfolio concen significant potential growth trate resource key vitamin fine chemical human resource medicinal feed additive busi nessverystrong sale growth acquisition ofaustriabase avls medical instrument business lead amarke increase headcount diagnostic divisionavl medical instrumentsemployee rapidly integrate divisionand success determine large measure thepersonnel adjustment need toeliminate duplication imple qualification motivation employee mente socially responsible continue promote performancebase fashionthe cost wagessalarie andemployee benefit total culture intend company good people million swiss franc want work new technology ongoing realign daniel villiger head corporate service ment response change market need continue tough de mand flexibility dedica continue development make tough tionof employeesdisplaying demand end high level motivationskill pro roche group employ people fessionalismthey meet chal worldwidethis lenge rapid structural change figuredue spinoff master increasingly complex task fragrance flavours division enhance roche mid divestment formance vitamin fine chemical division human resourcesheadcount division year end itsduethis support identify change change critical performance area create pharmaceutical individual development plan diagnostic employeeswe reward high achiever vitamin fine chemical performancebase salary compo fragrance flavours nentsa system continue toextend additional management roche group level roche offer wide range attractive career opportunity headcount region year end employee development potential europe aboveaverage commitment switzerland north america executive committee decide latin america continue groupwide workshops asia conduct explain dis africa australia oceania cuss roches corporate principle total issue relate behaviour busi nesswith addition new topic subject cover continual expansion leadership europewide programme design phase protection personal skill professional ability promote international experience shar datathe use roche electronic com social competence ing transfer knowhowthe munication toolsand business step effort provide vitamin fine chemical division integritythe programme design employee firstrate opportunity revamp management develop impart rule behaviour busi personal professional develop ment succession planningwith ness enable roche employee mentthis primarily offer main focus prepare successor perform task way e challenge management position key post exemplary respectwe firmly local international levelsmany believe business practice base involve complex project september see groundbreak ethical social management tasksroche encourage ing ceremony roche new interna environmental responsibility continuous assessment train tional training conference centre safety environmental protection development need middle senior managersroche forum p cornerstone commer senior manager prepare buonaswhich establish cial success postsin roche initiate scenic buona peninsulalake zug groupwide programme indi switzerlandthe new complex vidual focus develop leadership incorporate conference areameeting skill collaboration london roomsa restaurant accommo business schoolseveral dation wingif ambitious timetable senior manager roche affiliate metwe expect centre oper worldwide ational early programmewhich run similar programme commitment performance culture implement extensively phar ethical business practice maceutical divisionin autumn roche management culture diagnostic division start formancebase excellence human resource safety environmental protection pation chemical industry world wide responsible care programme andother initiativeswe take initiative efficient solution help improve community acceptance roche production locationsin sowe conscious dynamic interdependence safety product process economicenvironmental social issue protection employee environment unwanted effect activity essential give nature manufacturing activitiesour principal aim pro roche longterm success mote ecoefficiency continually hans knzi head corporate safety environmental protection improve exist production process replace fun damentally new onesaccordingly sustainable development inno integrate safety environmental vativeglobally active healthcare group protection control account roche commit put substantial roche total se principle sustainable development expenditure practice responsibly appro priatelywe intend maintain accident incident high healthsafety envi roche remain free major ronmental protection se standards incidentsunfortunatelyhoweverwe continually improve performance report accident areasa show partici plant china claim safety environmental protectionlife young employeethe fatal safety environmental protection expenditure millions chf ity group facility yearsit cause human errora factor investment sophisticated safety operating cost measure completely offset total expenditure incident involve firesone factory morocco coalfire power plant china organisation body french produc significant reduction include oecdilo cefic tion facilitieswhich result prop achieve emission volatile working improve safe manage erty damage organic compound vocsthough ment chemicalswe particularly emission level vary site active programme focus overallthe number occupational tosite owe vary production high production volume chemicalsin accident remain previous volumesour contribution envi past year chemical indus year low levelan achievement ronmental protection receive try launch number interna trainingcontinuing education public recognitionimplementation tional initiative speed rigorous se audits newecoefficient synthesis activity improve knowledge group certainly important antiviral agent ganciclovir enable chemical worldwide large contribution se audits conduct reduction wastefor quantitiesin additionroche roche facility country facility boulder colorado receive major contributor global chemi confirm group uniformly presidential green chemistry cal industry longrange research ini highhealthsafety environmental challenge awardin mexico tiativewhich aims increase standardsthis positive trend facility cuernavaca receive understanding way reflect award roche facility clean industry award chemical interact human factory clarecastle ireland body environment receive award national irish total volume chemical waste safety organisation depart decline far steeply produc ment enterprisetrade employ tion volumesuccessful implementa ment log million man tion policy eliminate sub hour lost worktime stance contribute depletion accidentsand plant florence ozone layer replace north carolina similarly hon alternative solution continue oure occupational safety roche take important step health administration goal sustainable development introduction fermenta successful environmental protection tion process vitamin b production measure good environmental thank new processconsump protection record previous year tion nonrenewable raw material maintain overallalthough problem reduce voc emission atmospheric emission lead emission water investigation authoritie moreoverthe result waste com group companyenergy consumption postableallowe natural recycling decline slightlyin step modest drop production volumeby con commitment sound environmental trastco emission increase policy year roche con yearfollowing acquisition tribute expertise international safety environmental protection finance roche achieve record net income chf billion increase previous year operating result enhance place genentech share market contribute chf bil lion group operating profit chf billion group net income addition finance treasury operation contribute strong net financial income chf billion include gain sale labcorp share adjust basis exclude effect item change accounting policy fragrance flavours business spin june group net income increase result strong cash flow roche year corange acquisition net creditor net liquidity position chf billion ratio equity minor ity interest total asset improve financefinancial review highlight millions chf figure report figure report financial statement adjust basis change change sale ebitda operating profit net income record result roche group achieve record result consolidate sale reach billion swiss franc increase previous year ebitda increase billion swiss franc operating profit reach billion swiss franc rise compare net income rise billion swiss franc result drive high operate financial income substantial gain sale genentech labcorp share adjust basis result roche group reflect strong performance group sale rise billion swiss franc ebitda increase billion swiss franc operating profit billion swiss franc net income billion swiss franc adjust figure present improve comparability current future result give show continue basis fragrance flavours business adjust accounting effect special item change international accounting standard description adjustment give roche record record profit net income rise previous year billion swiss franc henri b meier chief financial officer december doubledigit sale growth diagnostic sale growth pharmaceutical reduce patent expiry generic competition report group sale growth influence spinoff givaudan june adjust basis ie exclude sale fragrance flavour roche group achieve growth rate swiss franc local currency furthermore sale ofthe medicinal feed additive mfa product influence topline result exclude mfa fragrance flavours group post sale growth swiss franc local currency financial review growth rate swiss franc local currency sale diagnostic division outpace market sale patient care molecular system molecular biochemical grow doubledigit rate local currency pharma sale rise swiss franc local currency good performance certain establish new product mabtherarituxan herceptin neorecormon cellcept roaccutanaccutane partially offset generic competition verse ticlid united states patent expire strong start sale xenical level sale vitamin finechemical division increase swiss franc decline local currency exclude mfa product sale volume continue grow strongly price level ayear decline average stabilise increase ebitda operating profit group ebitda increase billion swiss franc operating profit increase billion swiss franc main driver strong result increase gross profit substantial gain sale genentech share absence unprovide expense settle vitamin case gross profit margin remain stable mar kete distribution cost grow fast sale exploit market potential establish new product net operating income reflect gain continue realignment product portfolio adjust basis ie exclude special item change accounting policy fragrance flavours business ebitda rise billion swiss franc operating profit billion swiss franc roche far high amortisation charge large pharmaceutical company result acquisition instead merger use international accounting standard amortisation charge billion swiss franc sale compare sale main competitor ebitda margin diagnostic pharmaceutical remain practically unchanged vitamin ebitda margin decline slightly result low average price givaudan spinoff complete june fragrances flavours division list swiss exchange independent company givaudan share givaudan distribute special dividend holder roche share nonvoting equity security onefor onebasis annual impact spinoff result roche group show adjusted figure reduction sale operating profit net income acquisition kytril strengthen roche oncology portfolio december roche acquire global right kytril billion dollars smithkline beecham connection merger glaxo wellcome kytril achieve net sale million swiss franc roche sell smithkline beecham exclusive rightsto coreg united states canada million dollar substantial gain sale genentech share march group sell million share genentech public offering yield proceed billion dollar result pretax gain incidental cost billion swiss franc roche hold genentech correspond approximately majority holding acquire financial reviewmajor step settle vitamin case united states roche complete major step settle vitamin case united states march federal judge approve overall settlement agreement class action suit bring buyer bulk vitamin customer class action decide opt overall settlement pursue claim group individually october overall agreement indirect customer endconsumers united states announce outside united states european commission issue astatement objection july producer bulk vitamin include roche global provision record remain current good estimate total liability strong financial result total financial income reach billion swiss franc strong positive result primarily drive net gain sale marketable security include share labcorp june labcorp call redemption entire convertible preferred stock hold roche portfolio investment conversion process roche realise pretax gain million swiss franc october roche reduce hold labcorp realise pretax gain million swiss franc gain october sale exclude adjusted result capacity generate high cash flow solid financing highly flexible equipped future anton affentranger chief financial officer january financial condition strengthen group achieve impressive cash flow gross cash flow group ebitda increase billion swiss franc reflect improvement operating result include gain sale genentech share furthermore improvement work e capital turnover financial income contribute substantially net liquidity strength ene billion swiss franc total year december net liquidity amount billion swiss franc compare net debt billion swiss franc december ratio equity minority interest total asset increase atyearend end offset impact new revise international accounting standard new revise standard issue international accounting standard committee effective january effect change accounting policy business combination intangible asset billion swiss franc largely offset impact new standard impairment asset billion swiss franc accounting effect major acquisition report aconsistent manner financial review consolidated income statement millions chf figure report figure report financial statement adjust basis change change sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset operating income expense net gain sale genentech share vitamin case genentech legal settlement operating profit financial income expense net profit taxis income taxis profit taxis change accounting policy income applicable minority interest share result associate company net income dilute earning share nonvoting equity security chf adjust resultsthe consolidated result significantly influence special item change international accounting standard improve comparability current future consolidated result adjust figure calculate year internal management business helpful reviewing trend group result adjust result show continue basis result fragrance flavours division exclude givaudan spinoff take place january sale vitamins fine chemical division fragrance flavours division reclassify sale party adjust result exclude gain sale genentech share gain sale labcorp share inoctober cost vitamin case genentech legal settlement adjust result recur accounting effect new revise international accounting standard effective january acquisition remain outstanding share genentech take place begin adjusted figure exclude charge record second half relate fairvalue adjustment inventory associate genentech acquisition adjustment lead correspond modification income taxis income applicable tominority interest minority interest figure calculate participation genentech december apply analysis adjustment give explanation adjust item give note consolidated financial statement financial reviewsale adjust basis million chf change change local division chf currency pharmaceutical diagnostic vitamin fine chemical total sale gross profit gross profit increase million swiss franc billion swiss franc gross profit margin remain adjust basis ie exclude primarily fragrance flavours gross profit reach billion swiss franc increase billion swiss franc onthis basis gross profit margin remain stable gross profit margin improve favourable change division mix high share highmargin busi nesse productivity improvement division offset contin ued pressure price particular vitamin fine chemical anda new generation ofproduct diagnostic increase production service cost marketing distribution marketing distribution expense increase million swiss franc billion swiss franc adjust basis ie exclude fragrance flavour marketing distri bution expense rise billion swiss franc billion swiss franc major factor involve increase effort pharmaceutical build market xenical tamiflu increase support new oncology product premarkete expense upcoming product launch factor increase marketing spend diagnostic foster lead position industry build new market research development rise research development cost exclusively attributable genen tech inlicense collaboration agreement increase spending laterstage clinical trial exclude genentech research development cost remain level research development cost percentage sale group level stable pharmaceutical account group research development expense remain administration administration cost grow adjust basis ie exclude fragrance flavour increase slightly great growth sale mainly result increase legal cost competitive condition governmental inquiry offset ting saving improve process amortisation intangible asset significant increase amortisation expense primarily drive halfyear amortisation intangible asset goodwill result acquisition remain outstanding genentech share june adjust basis increase amortisation intangible asset primarily foreign currency effect impairment longterm asset adoption new international accounting standard result impairment charge billion swiss franc relate intangible asset acquire prior impairment entry result net impairment credit million swiss franc show theadjuste result financial review operating income expense net operating income expense net increase billion swiss franc mainly high gain ongoing realignment product portfolio high royalty income despite increase royalty restructuring expense operate profit operating profit rise billion swiss franc primarily drive increase gross profit billion swiss franc gain sale genentech share unpro vide expense vitamin case operating profit adjust basis increase billion swiss franc margin sale adjust basis decline divisional result adjust basisin million chf vitamin pharma fine ceutical diagnostic chemical group year end december divisional sale party ebitda sale operate profit sale year end december divisional sale party ebitda sale operate profit sale ebitda earning interest financial income tax depreciation amortisation include impairment measure gross cash generation division divisional operate profit margin furthermore reflect different fix asset intensity business acquisition history ebitda margin pharmaceutical division remain high marketing costsfor xenical tamiflu new oncology product premarkete expense upcoming product launch offset high sale improve gross profit margin andby gain continue realignment product portfolio diagnostic division maintain ebitda margin high marketing effort lead correspondingly high sale operating profit margin increase percentage point strong longterm competitive pressure vitamin fine chemical business con tinue division able offset sale price decline extent furtherproductivity improvement volume increase ebitda decrease percentage point result consist cost corporate headquarters increase substantially restructuring cost relate basel institute immunology vol untary solidarity contribution holocaust victim asset litigation swiss bank litigation financial reviewfinancial income expense net total financial income expense net show substantial increase billion swiss franc key factor profit achieve marketable security portfolio despite weak stock market gain sale labcorp share reduce group participation gain portfolio investment labcorp convertible high net liquidity available interest income increase substantially increase largely compensate rise interest expense result additional debt increase discount value provision net result foreign exchange transaction improve compare previous year exclusion gain theoctober saleof labcorp share total financial income expense net rise analysis component give note consolidated financial statement net income net income rise billion swiss franc represent return sale adjust basis increase amount balance sheet million chf change longterm asset current asset total asset equity minority interest noncurrent liability current liability total equity minority interest liabilitie notable factor development group balance sheet year spinoff givaudan exclude asset billion swiss franc liability bil lion swiss franc roche group balance sheet significant development acquisition global right kytril billion dollar add intangible asset change accounting policy group reclassify reduction equity billion swiss franc equity instrument previous year report marketable security record earning fed genentech labcorp share sale strong result ongoing activity largely responsible turn net debt position billion swiss franc start year net liquidity position billion swiss franc end help raise group ratio equity minority interest total asset period knock bond repay maturity helveticus convertible bond exercise consequent reduction group borrowing offset issue sumo lyon bond implementation new revise international accounting standard intangible asset business combination january result increase billion swiss franc intangible asset reduction intangible asset similar magnitude arise follow ing implementation new standard impairment asset date net effect balance sheet minor change purely account nature impact group cash flow financial review cash flow millions chf operating activity income taxis income taxis pay activity operating activity financing activity invest activity net effect currency translation cash increase decrease cash cash flow operating activity income taxis increase billion swiss franc improved operating result well work capital performance reduce outflow respect vitamin case restructure income taxis pay considerably high mainly genentech labcorp share sale financing activity cash flow benefit billion swiss franc proceed issue sumo lyon iv bond exceed outflow theknock helveticus bond billion swiss franc proceed genentech labcorp transaction partly kytril acquisition billion swiss franc addition property plant equip ment billion swiss franc remainder reinveste net purchase marketable security net cash outflow investing activity billion swiss franc foreign exchange rate exchange rate swiss franc december average december average december usd eur gbp jpy compare dollar average strong swiss franc theeuro weak net effect differ exchange rate pattern group sale positive percentage point dollar strengthen swiss franc yearend basis contrast theweakene euro japanese yen divergence trend tend mitigate effect group balance sheet financial reviewchfusd exchange rate j f j j n introduction euro introduction euro present opportunity streamline conduct business regard system business process system european group company adapt handle eurodenominate transaction company con cerne able deal dualcurrency transaction transition period locate emu country convert euro accounting purpose course financial review consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement million chf year end december sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset operating income expense net gain sale genentech share vitamin case genentech legal settlement operating profit financial income expense net profit taxis income taxis profit taxis change accounting policy income applicable minority interest share result associate company net income basic earning share nonvoting equity security chf dilute earning share nonvoting equity security chf consolidated financial statementsconsolidate balance sheet millions chf december longterm asset property plant equipment intangible asset investment associate company investment defer income tax asset longterm asset total longterm asset current asset inventory account receivable trade current income tax asset current asset marketable security cash total current asset total asset equity share capital nonvoting equity security genussscheine pm pm equity instrument retain earning reserve total equity minority interest noncurrent liability longterm debt defer income tax liability liabilitie postemployment benefit provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable trade accrue current liability total current liability total equity minority interest liability pm pro memoria nonvoting equity securities nominal value note consolidated financial statement consolidate statement change equity million chf year end december share capital balance january december nonvoting equity security genussscheine balance january december pm pm equity instrument balance january previously report adjustment change accounting policy balance january restate movement year balance december retain earning balance january net income dividend pay givaudan spinoff special dividend transfer net asset balance december reserve equity conversion option conversion option embed sumo bond currency translation difference balance january gain loss recognise year balance december balance reserve december total equity december pm pro memoria nonvoting equity securities nominal value note consolidated financial statementsconsolidate cash flow statement million chf year end december cash flow operating activity net income nonoperate income expense operate profit depreciation property plant equipment amortisation intangible asset impairment longterm asset effect genentech transaction vitamin case genentech legalsettlement adjustment noncash operating income expense increase decrease work capital cost vitamin case pay cost genentech legal settlement pay restructuring cost pay payment define benefit postemployment plan operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow financing activity proceed issue longterm debt repayment longterm debt transaction equity instrument increase decrease shortterm borrowing interest dividend pay givaudan spinoff special dividend givaudan cash balance total cash flow financing activity cash provide operating financing activity cash flow invest activity purchase property plant equipment intangible asset disposal property plant equipment intangible asset acquisition subsidiary associate company product divestment subsidiary associate company product interest dividend receive purchase marketable security net sale total cash flow investing activity net effect currency translation cash increase decrease cash cash begin year cash end year nonoperate income expense consist follow income statement item financial income expense net income taxis change accounting policy income applicable minority interest share result associate company consolidate financial statement note consolidated financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international accounting standard historical cost convention authorise issue board director february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assump tion modify appropriate year circumstance change consolidation policy financial statement consolidate financial statement roche holding ltd acompany register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enter prise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right company share capital company acquire year consolidated date operating control transfer group subsidiary divest include date divestment company acquire resold consolidated classify asset hold sale carry cost asset identify divestment follow year reclassify asset hold sale current asset asset normally consist mainly inventory property plant equipment longterm asset investment associate company account equity method com panie group exercise significant influence control isnormally evidence group own voting right company interest joint venture report linebyline proportionate consolidation method investment carry cost deduct appropriate provision permanent impairment include longterm asset note consolidated financial statementsforeign currency valuation asset liability group company report currency swiss franc foreignentitie translate swiss franc yearend rate exchange sale costsexpense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity exchange gain loss hedge nonswiss franc net investment intercompany balance longterm investment nature take equity divestment foreign entity cumulative currency translation difference relate foreign entity recognise income gain loss ondivestment gain loss exchange arise group company translation local reporting currency financial asset liability denominate foreign currency settlement foreign currency transaction include income certain group company maintain financial information group report purpose dollar swiss franc euro functional currency company concern effect exchange rate difference local currency usdollarswiss franc euro respect financial asset liability include income sale cost sale sale represent amount receive receivable good supply service render customer deduct volume discount sale taxis cost sale include cor respond direct production cost relate production overhead good manufacture service render research development research cost charge income incur exception building major item equipment capitalise depreciate development cost charge income incur criterion recognition asset notmet employee benefit wage salary social security contribution pay annual leave sick leave bonus option nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned group operate number define benefit define contribution plan world cost year define benefit plan determine project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return planasset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested pension asset liability different define benefit scheme offset group legally enforceable right use surplus plan settle obligation plan note consolidated financial statement group contribution define contribution plan charge income statement year relate taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base onincome property capital taxis include operating expense financial expense accord nature provision income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary current inten tion remit earning defer income taxis provide liability method defer tax conse quence recognise temporary difference tax basis asset liability carry value financial reporting purpose defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow building land improvement year machinery equipment year office equipment year motor vehicle year investment grant similar assistance project initially record deferred income inoth noncurrent liability subsequently recognise income useful life relate asset repair maintenance cost recognise expense incur borrowing cost capitalise asset acquire finance lease depreciate estimate useful life payment operating lease charge income straightline basis period lease inventory inventory state low cost net realisable value cost determine firstout method cash marketable security cash comprise cash hand time current balance bank similar institu tion definition cash flow statement marketable security show low cost market value note consolidated financial statementsdebt instrument proceed net expense bond issue warrant allocate bond warrant proportion respective fair market value time issue discount arise low coupon rate represent difference prin cipal net proceed charge interest expense life bond obligation arise warrant issue debt instrument accrue period thewarrant outstanding meet maximum cash obligation date warrant exercisable provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate financial instrument gain loss forward exchange contract option currency swap hedge potential exchange rate exposure defer offset loss gain specific transaction hedge fee agree establish contract amortise duration contract interest differential swap arrangement forward rate agreement interest rate cap manage interest rate exposure recognise adjustment interest expense derivative financial instrument trading purpose gain loss change market value take income arise certain cover option contract enter group require underlying security lodge financial institution involve arrangement fair value balance sheet date approximately line report carry value specifically mention note consolidated financial statement international accounting standard revise new standard issue international accounting standard committee interpretation standing interpretation committee effective january list effect describe total recur operating cost million swiss franc higher previous method accounting recording effect change accounting policy group follows allow alternative retain previous year figure report ofdisplaye effect current year income statement property plant equipment provision contingent liability contingent asset event balance sheet date adjustment necessary result implementation group accounting policy previously reflect measurement prin ciple new revise standard share capital reacquire equity instrument group holding equity instrument record deduction equity original cost acquisition considera tion receive subsequent resale equity instrument movement report change equity previously instrument record marketable securi tie treat equity instrument report earning share approximately high instrument acquire primarily meet obligation arise respect certain group debt instrument note consolidated financial statement impairment asset recoverable asset high net selling price value use carrying carry reduce recoverable value reduction report income statement impair ment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate previously value use calculate cash flow projection undiscounte basis new standard require adopt prospective basis result effective january group recognise impairment charge million swiss franc relate acquire intangible asset reduction defer tax liability million swiss franc record give net charge million swiss franc consolidated result group previous accounting treatment impairment arisen result impairment net book value intangible asset reduce impairment charge consequently amortisation million swiss franc lower previous policy impairment entry arise year disclose note intangible asset business combination goodwill record intangible asset surplus cost acquisition fair value identifiable asset acquire goodwill fair value adjustment treat asset liability acquire company record local currency company patent licence trademark intangible asset initially record fair value asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost intangible asset amortise useful life straightline basis estimate useful life major class intangible asset follow goodwill year patent licence trademark low legal duration intangible asset economic useful life maximum year require implementation new revise standard group review account previous acquisition process include acquisition genentech nicholas syntex tastemaker corange group recalculate goodwill asset liability arise significant acquisition adjust carry ing value accordingly require new revise standard furthermore connec tion acquisition prior group report intangible asset goodwill previously writtenoff equity recalculate goodwill asset andliabilitie arise acquisition accounting effect group acquisition report consistent manner addition nonacquisitionrelate intangible asset review ensure meet recognition measurement criterion ofthe new standard result january group record certain reclassification adjustment original purchase accounting allocation reflect revise balance approximate amortisation january effect taxation balance minority inter est follow note consolidated financial statementsother defer intangible income minority millions chf goodwill asset tax interest total item previously recognise provision charge expense transfer prior change group organisation amortisation net defer income tax effect net minority interest net credit income result change accounting policy carrying value intangible asset increase january consequently group amortisation charge million swiss franc higher previous policy increase diagnostic division new revise standard intangible asset business combination apply group net asset december high million swiss franc recur operating cost million swiss franc higher report new standard consolidate financial statement new interna tional accounting standard financial instrument recognition measurement come effect standard require financial asset financial liability recognise balance sheet include derivative financial statement affect intro duction fair value account certain marketable security investment derivative certain marketable security investment designate available sale group intend recognise change fair value equity asset sell assessment impact standard group financial position january report consolidated financial statement adjustment retain earning january restatement previously report amount year end december result retain earning increase approximately billion swiss franc significant relate investment fair value approximately billion swiss franc high carrying value december new international accounting standard investment property effective january expect significant impact group financial statement international accounting standard continue develop revise future lead adaptation group accounting policy come year financial risk management financial risk management group govern policy approve senior manage ment policy cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy cover area cash management investment excess fund raise short longterm debt note consolidated financial statement deem appropriate certain risk alter use financial instrument group management believe order create optimum value group desirable eliminate mitigate possible market fluctuation financial instru ment selectively create optimise value group company report detail financial instrument outstanding financial liquidity position group treasury monthly basis foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc transaction exposure arise local currency pay receive trans action denominate foreign currency vary change exchange rate group company income primarily local currency significant expen diture especially purchase good resale interest repayment loan foreign currency similarly transaction exposure arise net balance monetary asset hold foreign currency group company manage exposure local level necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure help comprehensive datum receive monthly basis translation exposure arise consolidation foreign currency denominate finan cial statement group foreign subsidiary effect group consolidated equity show currency translation movement group hedge significant net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regular basis significant group cash outflow research development production admin istration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc rela tive currency adverse impact consolidate net income similarly relative fall value swiss franc favourable effect result publish swiss franc interest rate risk interest rate risk arise movement interest rate adverse effect thegroup net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk interest rate group major debt instrument fix describe note reduce group exposure change interest rate group company manage shortterm interest rate risk local level necessary financial instrument interest rate forward contract swap option market risk change market value certain financial asset liability instrument affect net income financial position group group longterm investment hold strategic purpose change market value affect carry value perma nent loss value indicate group marketable security hold fund management purpose risk loss value reduce careful review prior invest concen tration investment continuous monitoring performance investment change risk configuration note consolidated financial statementscredit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focusse assessment country risk credit availability ongoing credit evaluation account monitor procedure significant concentration trade receivables counterparty credit risk dueto group large number customer wide geographical spread country risk limit exposure continuously monitor exposure financial asset liability credit risk control set policy limit credit exposure highquality counterpartie continuously review credit rating limit individual aggregate credit exposure accordingly liquidity risk group company need sufficient availability cash meet obligation individual company responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group allow efficient use international capital market financing pur pose group organisation overview operating subsidiary associate company include page addition operating company group hold finance company genentech june group exercise option acquire remain outstanding special common stock genentech inc june result genentech wholly own subsidiary group total consideration million dollar million swiss franc include contribution group genentech fund require genentech purchase outstanding genentech special common stock cost genentech settle outstanding obligation employee stock option plan consid eration pay allocate asset liability genentech consequently total carrying value genentech increase million swiss franc group record writeup inventory million swiss franc million swiss franc recognise cost sale sale inventory million swiss franc july october group sell total common stock genentech public offering yield total proceed billion dollar billion swiss franc total result pretax gain billion swiss franc calculate difference proceed sale net incidental cost proportion net asset march group sell million share genentech public offering yield proceed million dollar million swiss franc result pretaxgain incidental cost million swiss franc roche ownership interest ingenentech december note consolidated financial statement acquisition divestment december group acquire global right kytril granisetron smithkline beecham cash consideration million dollar million swiss franc december group sell exclusive right coreg carvedilol united states canada smithkline beecham million dollar million swiss franc group remain supplier carvedilol market outside united states canada result acquisition kytril acquisition medical instrument division avl certain small acquisition additional intangible asset million swiss franc record total cash outflow acquisition million swiss franc inflow divestment million swiss franc note consolidated financial statement segment information millions chf divisional information vitamin fragrance pharma fine continue ceutical diagnostic chemical operation flavour group segment revenue segment revenue divisional sale interdivisional salesa divisional sale party segment result operate profit segment asset liabilitie divisional assetsb segment assetsc segment asset nonsegment assetsd total asset divisional liabilitiesb segment liabilitiesc segment liability nonsegment liabilitiesd total liability segment information capital expendituree depreciation amortisation impairment longterm asset research development cost share result associate company investment associate company number employee transfer price interdivisional sale set arm length basis b divisional asset consist primarily property plant equipment intangible asset receivables inventory divisional liability consist trade account payable c segment asset liability consist asset liability reasonably attribute report business segment include pension asset liability provision nonsegment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment associate company investment debt e capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition note consolidated financial statement vitamin fragrance pharma fine continue ceutical diagnostic chemical operation flavour group segment revenue segment revenue divisional sale interdivisional salesa divisional sale party segment result operate profit segment asset liabilitie divisional assetsb segment assetsc segment asset nonsegment assetsd total asset divisional liabilitiesb segment liabilitiesc segment liability nonsegment liabilitiesd total liability segment information capital expendituree depreciation amortisation research development cost share result associate company investment associate company number employee transfer price interdivisional sale set arm length basis b divisional asset consist primarily property plant equipment intangible asset receivables inventory divisional liability consist trade account payable c segment asset liability consist asset liability reasonably attribute report business segment include pension asset liability provision nonsegment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment associate company investment debt e capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition note consolidated financial statementsgeographical information sale party destination segment assetsa capital expenditureb switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assetsc consolidate total switzerland european union rest europe europe north america latin america asia africa australia oceania segment total nonsegment assetsc consolidate total segment asset consist primarily property plant equipment intangible receivables inventory segment liability include b capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition c nonsegment asset mainly include current defer income tax asset financial asset principally cash marketable security investment associated company investment vitamin case follow settlement agreement department justice pricing practice vitamin market group record pretax expense million swiss franc respect vitamin case cash outflow million swiss franc march federal judge approve overall settlement agreement class action suit bring buyer bulk vitamin customer class action decided opt propose settlement pursue claim group individually individual suit process possible determine timing ultimate settlement claim note consolidated financial statement october settlement agreement execute attorney general private class counsel represent indirect purchaser consumer state attor neys general respect governmental entity state class action settlement remain subject court approval approve roche pay million dollar plus interest legal fee certain suit state process possible determine outcome claim july european commission issue statement objection producer bulk vitamin include roche beginning commission formal investi gationinto vitamin case possible determine ultimate outcome investigation provision record respect vitamin case december amount utilise remain group good current estimate total liability arise additional expense charge net cash inflow million swiss franc follow optout buyer bulk vitamin settlement agreement group receive repayment amount pay trust fund genentech legal settlement november groups subsidiary genentech reach settlement agreement university california allege patent infringement involve genentech human growth hormone product furthermore genentech payment settle investigation united states federal authority relate past clinical sale marketing activity asso ciate human growth hormone total pretax expense record million swiss franc payment respect matter givaudan spinoff millions chf june groups fragrance flavours division spin independent company givaudan share givaudan distribute date special dividend holder roche share nonvoting equity security result spinoff asset total billion swiss franc liability total billion swiss franc transfer givaudan result cash flow fragrance flavour division spinoff june include consolidated figure consolidated balance sheet show spinoff include division asset liability sale result asset liability net cash flow fragrance flavour division roche group show discontinue operation follow table note consolidated financial statementscontinuing operation discontinuing operation group group statement income sale interdivisional sale sale party operate profit financial income expense net result taxis income taxis result taxis change accounting policy minority interest share result associate company net income balance sheet december property plant equipment intangible asset longterm asset current asset total asset longterm debt noncurrent liability current liability total liability net asset statement cash flow operating activity financing activity invest activity net effect currency translation cash increase decrease cash transfer price interdivisional sale set arm length basis note consolidated financial statement employee benefit million chf amount recognise arrive operating profit follow wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan employee benefit total employee remuneration number employee yearend postemployment benefit employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic con dition country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally usa plan usually fund payment group employee trust independent ofthe group finances plan unfunded liability obligation record group balance sheet amount recognise arrive operate profit postemployment define benefit plan follow current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment total include employee remuneration actual return plan asset million swiss franc million swiss franc note consolidated financial statementsthe movement net asset liability recognise balance sheet postemployment define benefit plan follow begin year previously report effect implement revise international accounting standard employee benefit restate change group organisation givaudan spinoff total expense include employee remuneration contribution pay benefit pay unfunded plan currency translation effect end year amount recognise balance sheet postemployment define benefit plan follow unfunded plan recognise asset liability actuarial present value unfunded obligation past present employee fund plan actuarial present value fund obligation past present employee plan asset hold trust fair value plan asset excess actuarial present value fund obligation unrecognised actuarial gain loss unrecognise past service cost recognise asset liability fund obligation past present employee asset liability recognise deficit recognise liabilitie postemployment benefit surplus recognise longterm asset total net asset liability recognise amount include nonpension postemployment benefit scheme principally medical plan actuarial present value obligation million swiss franc million swiss franc plan asset million swiss franc million swiss franc relate net liability recognise million swiss franc million swiss franc actu arial gain million swiss franc million swiss franc unrecognised amount recognise balance sheet postemployment define benefit plan predom inantly noncurrent report longterm asset noncurrent liability note consolidated financial statement include fair value asset fund plan group nonvoting equity security fair value million swiss franc million swiss franc group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption theactuarial valuation significant define benefit plan country stable currency interest rate follow discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate operating income expense net millions chf royalty income operating income total operating income royalty expense restructure expense operate expense total operating expense total operating income expense net financial income expense net millions chf gain sale marketable security loss sale marketable security net gain sale marketable security interest dividend income interest expense exchange gain loss net total financial income expense net income taxis million chf income tax expense amount charge income statement follow current income taxis defer income taxis total charge income taxis group parent company roche holding ltd group operate company domicile switzerland maximum effective rate income taxis company domicile basel switzerland hold company operate company group operate world subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate note consolidated financial statementsthe group effective tax rate differ group expect tax rate follow group average expect tax rate tax effect income taxable expense deductible tax purpose benefit prior year tax loss previously recognise difference gain sale genentech share gain sale labcorp share impairment longterm asset vitamin case genentech legal settlement group effective tax rate income tax asset liability amount recognise balance sheet income taxis follow current income taxis current income tax asset current income tax liability net current income tax asset liability balance sheet defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability balance sheet amount recognise balance sheet defer taxis report longterm asset noncurrent liability approximately respectively current deferred income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group significant unrecognised tax loss defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year adjustment change accounting policy issue debt instrument charge credit income statement change group organisation givaudan spinoff currency translation effect net defer income tax asset liability end year note consolidated financial statement property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year adjustment change accounting policy charge credit income statement change group organisation currency translation effect net defer income tax asset liability end year property plant equipment million chf building land machinery improve construction land ment equipment progress total total net book value beginning year currency translation effect change group organisation include givaudan spinoff addition disposal transfer depreciation charge end year december cost accumulate depreciation net book value december capitalise cost machinery equipment finance lease amount million swiss franc million swiss franc net book value asset amount million swiss franc million swiss franc operating lease commitment december future minimum payment noncancellable operating lease follow year year total minimum payment total rental expense operating lease million swiss franc mil lion swiss francs group significant capital commitment purchase construction property plant equipment note consolidated financial statement intangible asset millions chf patent licence trademark goodwill total total net book value beginning year change accounting policy currency translation effect change group organisation include givaudan spinoff addition disposal amortisation charge impairment charge end year december cost accumulate depreciation end year january group recognise impairment charge million swiss franc implement change accounting policy note credit million swiss franc recognise base change recoverable amount impair asset year investment associated companiesin millions chf group investment associate company list equity investment asso ciate company account equity method share net income balance sheet value laboratory corporation america holdings usa investment account equity method total investment account equity method laboratory corporation america holdings usa nonvoting convertible mandatorily redeemable prefer stock cost total investment associated companies laboratory corporation america holdings group noncontrolle interest laboratory corporation amer ica holdings labcorp operate clinical laboratory united states labcorp create merger roche biomedical laboratories inc national health laboratory holdings inc roche own new company thegroup purchase nonvoting convertible prefer stock labcorp hold cost portfolio investment note consolidated financial statement june labcorp announce call redemption july outstanding convertible preferred stock redemption period group sell sufficient hold labcorp ordinary stock group noncontrolle interest labcorp similar level redemption date group realise pretax gain million swiss franc process october group sell share labcorp result pretax gain incidental cost million swiss franc transaction result total cash inflow million swiss franc basilea pharmaceutica october group contribute cash million swiss franc establish newly form swiss company basilea pharmaceutica ltd basilea group transfer certain knowhow intellectual property antibiotic antifungal dermatology property plant equipment basilea consideration million swiss franc october group sell share basilea group retain noncontrolle interest basilea longterm asset millions chf recognise surplus fund pension plan loan receivable prepay employee benefit total longterm asset loan receivable comprise loan party term year longterm asset consist asset show separately group expect toderive economic benefit year inventory million chf raw material supply work process finish good provision slow move obsolete inventory total inventory inventory hold net realisable value carry value million swiss franc million swiss franc account receivable trade millions chf account receivable note receivable provision doubtful account total account receivable trade december account receivable trade include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euros emu national currency equivalent billion swiss franc billion swiss franc note consolidated financial statement current asset millions chf accrue interest income prepaid expense asset hold sale receivables total current asset asset hold sale include inventory property plant equipment longterm asset product identify divestment follow year cash marketable security millions chf equity security bond debenture money market instrument total marketable security total cash total cash marketable security equity security consist primarily readily saleable security bond debenture contract maturity range interest rate year year year year year year weight average interest rate approximately bond debenture money market instrument generally fix interest rate range depend currency denominate contract mature year december december fair value marketable security approximately billion swiss franc approximately billion swiss franc accrue current liabilitiesin millions chf defer income accrue payroll relate item interest payable accrue liability total accrue current liability note consolidated financial statement equity share capital december authorise calledup share capital share nominal value chf base information supply roche shareholder group pool voting right comprise hoffmann oerihoffmann family group hold share precede year figure include share pooled voting right hold outside group individual member group transaction individual ordinary course business nonvoting equity security genussscheine december nonvoting equity security issue swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate inaccordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate equity instrument december group hold nonvoting equity security financial instrument acquire security acquire pri marily meet obligation arise respect certain group debt instru ment group holding equity instrument record deduction equity dividend shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribu tion holder outstanding share nonvoting equity security total million swiss franc charge retain earning shareholder approve special dividend respect givaudan spinoff accounting effect distribution primarily include carry value group financial statement asset liability givaudan total million swiss franc include special dividend movement retain earning earning share nonvoting equity security basic earning share nonvoting equity security net income millions chf number share thousand number nonvoting equity security thousand weight average number nonvoting equity security hold thousand total thousand basic earning share nonvoting equity security chf note consolidated financial statementsdilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security theweighte average number share nonvoting equity securities outstanding adjust assume conversion dilutive potential share nonvoting equity security net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue thousands adjustment assume conversion convertible debt instrument dilutive thousand weight average number share nonvoting equity security issue calculate dilutive earning share thousand dilute earning share nonvoting equity security chf minority interestsin millions chf beginning year change accounting policy givaudan spinoff acquisition genentech special common stock sale genentech share conversion option embed lyon iv note issue minority share group net income net tax exercise genentech stock option currency translation effect end year genentech total minority interest genentech december minority interest genentech publicly hold par tie group transaction genentech share describe note december genentech option outstanding employee stock option plan entitle holder exercise option purchase million share price range usd usd option outstanding million exercisable date note consolidated financial statement debtin millions chf amount bank financial institution debt instrument capitalise lease obligation borrowing total debt current portion longterm debt amount year total longterm debt shortterm debt total million swiss franc million swiss franc consist ofthe current portion longterm debt show table shortterm bank loan overdraft shortterm debt amount million swiss franc million swiss franc repayment term longterm debt year year year year year total longterm debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value longterm debt billion swiss franc billion swiss franc calculate base present value future cash flow instrument discount market rate interest instrument similar credit status cash flow amount bank financial institution interest rate amounts primarily denominate dollar euros emu national currency average approximately repayment date vary year debt instrument carry value group debt instrument give table supplementary information group debt instrument include redemption conversion term ifany give page note consolidated financial statementseconomic interest rate hold maturity swiss franc bond bullet principal billion swiss franc rodeo principal billion swiss franc dollar bond knock principal billion dollars bull spread principal billion dollar chameleon principal billion dollar japanese yen bond samurai principal billion japanese yen swiss franc convertible bond helveticus dividendlinke convertible bond principal billion swiss franc zero coupon dollar exchangeable note lyon ii principal billion dollar lyon iii principal billion dollar lyon iv principal billion dollar japanese yen exchangeable bond sumo principal billion japanese yen limited conversion prefer stock total debt instrument economic interest rate hold maturity market rate interest date issuance similar debt instrument conversion right discount issuance issue lyon iv dollar note exchangeable genentech share january group issue zero coupon dollar exchangeable note january principal million dollar note exchangeable share group subsidiary genentech time prior maturity note exchange genentech share group percentage ownership genentech decrease net proceed issue million dollar million swiss franc initially allocate million swiss franc debt million swiss franc unamortise discount million swiss franc minority interest respect conversion option embed note million swiss franc defer tax liability issue sumo japanese yen bond exchangeable nonvoting equity security april group issue japanese yen exchangeable bond march principal billion japanese yen bond exchangeable non vote equity security march net proceed issue billion japanese yen million swiss franc initially allocate million swiss franc debt million swiss franc unamor tise discount million swiss franc equity respect conversion option embed bond million swiss franc defer tax liability note consolidated financial statement repayment knock dollar bond date april group repay principal billion dollar dollar bond originally issue result cash outflow million swiss franc exercise helveticus swiss franc convertible bond helveticus dividendlinke swiss franc convertible bond principal million swiss franc exercise result cash outflow million swiss franc small amount exercise year swiss franc convertible bond annual payment distribution pay july bond chf par value place fix rate interest annual payment distribution equal timesthe ordinary andor extraordinary dividend declare nonvoting equity security roche holding ltd business year end december nineteen month priorto july relevant year unamortised discount include carry value debt instrument follow unamortised discount swiss franc bond dollar bond japanese yen bond swiss franc convertible bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount financial instrumentsin millions chf appropriate circumstance group use financial instrument risk management trading strategy discuss note majority derivative financial instru ments outstanding yearend consist forward contract enter foreign affiliate purchase currency settle intragroup liability notional principal value fair value carry value derivative financial instrument hold group show table notional amount represent amount actually exchange party measure group expo sure fair value determine reference quote market price use establish estimation technique carry value include consolidated balance sheet current asset accrue liability note consolidated financial statementsnotional principal carrying fair value value foreign currency derivative forward exchange contract swap option interest rate derivative swap derivative total derivative financial instrument foreign currency derivative forward exchange contract swap option interest rate derivative swap derivative total derivative financial instrument net unrecognised gain open contract hedge future anticipate foreign currency sale amount million swiss franc million swiss franc gain recognise income statement open contract mature date year balance sheet date provisionsin millions chf restructure provision provision total total beginning year change group organisation givaudan spinoff additional provision create unused amount reverse utilise year increase discount passage time change discount rate currency translation effect end year current portion provision noncurrent portion provision total provision restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructure asso ciate ongoing activity group creation provision record acharge operating income arise restructuring newly acquire company case include acquisition accounting form goodwill note consolidated financial statement provision consist mainly legal environmental similar matter provision include provision respect vitamin case note contingent liability operation earning group continue time time vary degree tobe affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency development event cover insurance effect future operation earning predictable provision record respect vitamin case disclose note provision group good current estimate total liability arise investigation outside united states america private civil suit progress ispossible ultimate liability different cash flow statement million chf cash flow operating activity cash flow operating activity derive group primary activity asdescribe divisional review calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation movement group work capital operating cash flow include income taxis pay activity include example thetaxe pay genentech labcorp share sale effect genentech transaction vitamin case genentech legal settlement gain sale genentech share charge vitamin case charge genentech legal settlement genentech inventory writeup charge total adjustment noncash operating income expense expense define benefit postemployment plan adjustment total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity note consolidated financial statementsproceed issue longterm debt lyon iv zero coupon exchangeable dollar note sumo exchangeable japanese yen bond chameleon dollar bond longterm bank loan borrowing total repayment longterm debt repayment knock dollar bond exercise helveticus dividendlinke swiss franc convertible bond longterm bank loan borrowing total interest dividend pay interest pay dividend pay total cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect change group organisation cash generate group investment cash flow marketable security include income capital gain loss show net movement group portfolio consist large number position hold longterm basis acquisition subsidiary associate company product cash contribution basilea acquisition genentech special common stock acquisition total divestment subsidiary associate company product proceed sale genentech share proceed sale labcorp share divestment total interest dividend receive interest receive dividend receive total note consolidated financial statement subsequent event annual general meeting april shareholder ask approve stock split share nonvoting equity security roche holding ltd ifapproved split place change relevant swiss company law enter force note consolidated financial statementsreport group auditor general meeting roche holding ltd basel auditor group audit consolidated financial statement roche group page year end december consolidated financial statement responsibility board director roche holding ltd responsibility express opinion consolidated financial statement base audit confirm meet swiss legal requirement con cerne professional qualification independence audit conduct accordance auditing standard promulgate swiss pro fession international standard auditing issue international federation accountant require audit plan perform obtain reasonable assurance consolidated financial statement free material misstate ment examine test basis evidence support amount disclosure theconsolidate financial statement assess accounting principle significant estimate overall consolidated financial statement presentation webelieve audit provide reasonable basis opinion opinion consolidate financial statement roche group present fairly material respect financial position december result operation cash flow year end accordance international accounting standard comply relevant swiss law recommend consolidated financial statement submit approve pricewaterhousecoopers ag william kirst ralph r reinertsen basel february report group auditor multiyear overview statistic report statement income millions chf sale ebitda operating profit net income research development balance sheet million chf longterm asset current asset total asset equity minority interest noncurrent liability current liability addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjusted chf warrant hold final exercise date b addition normal dividend shareholder approve share nonvoting equity security special ro centenary warrant worth chf date issue holder option cash equivalent chf c net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum multiyear overview c e f b e f warrant hold final exercise date e dividend include special dividend relate spinoff fragrance flavour division f dividend propose board director multiyear overview sale division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total sale geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america asia africa australia oceania total multiyear overviewconsolidate income statement adjust basis reconciliation report figure adjust basis million chf sale operate net party ebitda profit income report financial statement discontinue operation reclassification sale givaudan sale party impact fair value adjustment genentech inventory impairment longterm asset gain sale genentech share gain sale labcorp share income taxis change accounting policy income applicable minority interest adjust report financial statement discontinue operation reclassification sale givaudan sale party impact fair value adjustment genentech inventory impact newrevise ias additional amortisation genentech acquisition effective january gain sale genentech share vitamin case genentech legal settlement income taxis change accounting policy income applicable minority interest adjust consolidated income statement adjust basis hold finance company boehringer mannheim far east pte ltd singapore boehringer mannheim france hold sa meylan france corange deutschland hold gmbh mannheim germany corange ltd hamilton bermuda hoffmannla roche france sas neuillysurseine france roche capital corporation panama city panama roche capital market international limited st peter port guernsey roche capital transactions limited hamilton bermuda roche china limited shanghai china roche deutschland hold gmbh grenzachwyhlen germany roche financial management inc panama city panama roche financial product limited hamilton bermuda roche finanz ag basel switzerland roche hold uk limited welwyn garden city great britain roche holdings inc wilmington delaware usa roche international finance bermuda ltd hamilton bermuda roche international finance corporation limited st peter port guernsey roche international ltd hamilton bermuda roche kapitalmarkt ag basel switzerland roche pharmholde bv mijdrecht netherland roche treasury management europe ltd basel switzerland sapac corporation ltd montevideo uruguay syntex corporation panama city panama company wholly own group hold finance companiesroche security price development share chf roche share adjust swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security adjust swiss market index rebase price development american depositary receipt adr usd roche adr adjust sp index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july roche security number share nonvoting equity securitiesa number share nominal value chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity securityc chf net income equity dividend e f stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjuste share yearend nonvoting equity security yearend market capitalisation unadjuste millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share unadjuste priceearning nonvoting equity securitiesgenussscheine unadjusted nonvoting equity security genussscheinconfer right share participate available earning remain proceed liquidation follow repayment nominal value sharesand participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price stock price figure prior june adjust effect ofthe givaudan spinoff adjustment factor share nonvoting equity security factor independent financial institution c net income share market capitalisation figure assume equity instrument hold outstanding net income relate key ratio show special charge million swiss franc net tax incurredfollowe corange acquisition include corange respect balance sheet datum e dividend include special dividend relate spinoff fragrance flavour division f dividend propose board director ticker symbol share nonvoting american equity security depositary receipt reuter roczs roczgs rohhypk bloomberg ro sw rog sw rohhy swx swiss exchange ro rog roche securitiesoutstanding bond summarise bond term exchange term warrant bull spread warrant exercise holder face value usd warrant receive chf cash coupon issuer roche holdings inc roche holding ltd attach warrant relate roche bearer shares samurai warrant exercise june holder face value jpy billion warrant receive chf cash coupon issuer roche financial management inc roche holding ltd attach warrant relate roche nonvoting equity security genussscheine lyon april note exchangeable american depositary share face value usd adss adjust exchange ratio exchange coupon zero adss usd principal maturity note issuer roche holdings inc exchange ratio change accordance inden roche hold ltd ture agreement date april effective date exchange right roche adss june group purchase note cash option holder april purchase price perusd principal note usd addition note redeemable option group time april issue price plus accrue original issue discount oid helveticus july bond chf par value exchangeable non face value chf voting equity security roche hold ltd time coupon times ordinary andor extra life bond accordance term bond ordinary dividend nonvoting equity additional cash payment chf conver security genussscheine sion bond chf par value issuer roche capital market international limited roche holding ltd conversion right roche nonvoting equity security roche security outstanding bond summarise bond term exchange term warrant lyon note exchangeable american depositary share face value usd adss exchange ratio exchange adss coupon zero usd principal maturity note issuer roche holdings inc exchange ratio change accordance indenture roche holding ltd agreement date effective date june exchange right roche adss group purchase note cash optionof holder pur chase price usd principal note usd usd respectively addition note willbe redeemable option group atany time issue price plus accrue original issue discount oid rodeo march warrant entitle holder march exercise date face value chf receive cash payment chf average closing coupon price nonvoting equity security period march issuer roche kapitalmarkt ag relevant price chf roche holding ltd attach warrant roche b option group nonvoting equity security receive cash payment equal difference genussscheine relevant price chf relevant price chf chf ii buy nonvoting equity security exercise price chf accordance term warrant upper lower relevant price adjust june bullet march face value chf coupon issuer roche international finance corporation limit roche holding ltd chameleon july face value usd coupon issuer roche holdings inc roche hold ltd roche securitiesoutstanding bond summarise bond term exchange term warrant lyon january note exchangeable genentech share face value usd exchange ratio genentech share usd coupon zero principal maturity note group issuer roche holdings inc theright pay cash equal market value genen roche hold ltd tech share lieu deliver genentech share group exchange right purchase note cash option holder genentech common stock january january purchase price usd principal note usd usd respectively addition note redeemable option group anytime january issue price plus accrue original issue discount oid sumo march bond jpy par value exchangeable face value jpy nonvoting equity security roche holding ltd exchange coupon ratio bond redeemable maturity issuer roche holdings inc attheissue price plus accrue original issue discount roche holding ltd oid exchange right roche nonvoting equity security genussscheine accordance term bond exchange ratio adjust june roche security roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year financial statementsbalance sheet december millions chf longterm asset participation loan group company total longterm asset current asset account receivable group company account receivable prepay expense accrue income marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine pm pm general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company liabilitie accrue liability total current liability total liability total equity liability pm pro memoria nonvoting equity security nominal value financial statement note financial statement general financial statement roche holding ltd basel prepare accordance provi sion swiss company law accept business principle valuation method translation foreign currency balance sheet asset liability disclose net realisable value exception tothis rule participation show acquisition value appropriate writedown marketable security show low cost market value unrealise foreign currency gain balance sheet item defer expense income aswell foreign currency transaction translate exchange rate rule relevant transaction date detail specific item income total income million swiss franc million swiss franc higher previous year well operating increase financial income taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity total equity equal total asset previous year share capital previous year share capital amount million swiss franc consist bearer share nominal value chf nonvoting equity security previous year nonvoting equity security genussscheine nominal value guarantee guarantee favour group company total million swiss franc previous year million swiss franc time prepare balance sheet risk arise contingent liability discernible pledge asset asset total book value million swiss franc previous year million swiss franc pledge security company commitment note financial statementsparticipation major participation list page important shareholder share company issue bearer reason company notkeep register shareholder follow figure base information share holder shareholder validation check annual general meeting onother information available company previous year share shareholder group pool voting right comprise dr l hoffmann ms v michalskihoffmann ms hoffmann mr hoffmann ms v oeri hoffmann dr oeri ms duschmaloeri ms c oeri ms b oeri ms oeria previous year share bz gruppe hold aktiengesellschaft wilen switzer landb information supply shareholder december figure share include share pooled voting right hold outside group individual member group b figure december supply bz gruppe hold aktiengesellschaft note financial statement appropriation available earning proposal general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year distribution special dividend chf gross allocate share givaudan ltd share nonvoting equity security transfer free reserve total appropriation available earning carry forward account appropriation available earningsreport statutory auditor general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd basel year end december financial statement responsibility board director responsibility express opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss pro fession require audit plan perform manner obtain reasonable assurance financial statement free material misstatement examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate overall financial statement presentation believe audit provide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve ernst young ltd jrg zrcher philipp schaffter basel february report statutory auditor arctic circle tropic cancer roche tropic capricorn global market presence ct ia rcrc letic sale switzerland manufacture argentina research development australia service finance toll manufacture party austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt el salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt ia rcrc letic honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico morocco netherlands new zealand nicaragua norway pakistan panama peru philippine poland portugal puerto rico russia singapore south africa roche globale marktprsenz operating subsidiary associate company group hold interest switzerlandf hoffmannla roche ltd sa san jos roche servicios sa san mostofthe company list exception basel roche ltd sisseln teranol ltd jos roche costa rica sa san jos aremarke single dot lalden roche pharma switzerland ltd czech republic roche sro prague group interest reinach roche diagnostic schweiz denmark roche hvidovre dominican double dot group interest ltd rotkreuz roche diagnostic inter republic productos rochedominicana national ltd cham roche vitamin sa santo domingo ecuador roche europe ltd birsfelden roche instrument ecuador sa quito egypt rovigypt ltd december center ltd rotkreuz roche consumer giza roche egypt ltd giza el sal health ltd kaiseraugst basilea phar vador producto roche el salvador include change group membership maceutica ltd basel argentinaproduc sa san salvador finland roche oy february tos roche sa qumica e industrial espoo france hoffmannlaroche olivos australia roche product pty france sas neuillysurseine produit limit dee roche vitamin roche sa neuillysurseine roche australia ptylimite french forest diagnostic sa meylan roche vita syntex australia limited north sydney mine france sa villageneuf labo roche diagnosticsaustralia pty limited ratoire roche nicholas sa gaillard castle hill austria roche austria gmbh germany roche deutschland hold vienna roche diagnostic gmbh gmbh grenzachwyhlen corange vienna bangladesh roche bangladesh deutschland hold gmbh mannheim ltd dhaka belgiumnv roche sa hoffmannla roche aktiengesellschaft brussels sa citrique belge nv tienen grenzachwyhlen roche nichola roche vitamin nv deinzeastene deutschland gmbh eppstein dr schief roche diagnostic belgium sa brussels fer arzneimittel gmbh cologne roche bermuda syntex pharmaceutical diagnostic gmbh mannheim galenus international limited hamilton brazil mannheim gmbh mannheim hestia produto roche qumico e farmacuti pharma gmbh mannheim roche vita cos sa paulo colborndawe sa gmbh grenzachwyhlen great paulo canadahoffmannla roche britain roche product limit welwyn limited toronto roche vitamin canada garden city roche diagnostics ltd inc cambridge ontario chile producto lewes roche vitamin uk ltd welwyn roche ltda santiago de chile china garden city roche registration limited roche china limited shanghai shang welwyn garden city greece roche hel hai roche pharmaceuticals limited las sa athens guatemala producto shanghai roche taishan shanghai roche guatemala sa guatemala city vitamin products ltd shanghai roche honduras producto roche honduras sunve shanghai vitamins ltd shang sa tegucigalpa hungary roche hun hai roche new asiatic shanghai gary ltd budapest india roche scien vitamin ltd shanghai roche tific company india private limited zhongya wuxi citric acid ltd wuxi mumbai indonesia pt roche indonesia roche diagnostic shanghai limited jakarta ireland roche products ireland shanghai roche hong kong limited limited dublin roche ireland limited hong kong roche diagnostic hong clarecastle israel roche pharmaceuti kong limited hong kong colombia cal israel ltd telaviv italy roche producto roche sa bogot costa spa milan roche diagnostic spa rica producto roche interamericana milan istituto delle vitamine spa operating subsidiary associate companiesmilan japan nippon roche kk tokyo tary limited johannesburg south nutritec co ltd tokyo roche korearoche korea company ltd diagnostics kk tokyo roche vitamin seoul roche diagnostic korea co ltd japan kk tokyo malaysia roche seoul roche vitamin korea ltd seoul malaysia sdn bhd kuala lumpur roche spain roche farma sa madrid diagnostic malaysia sdn bhd kuala march roche vitaminas sa lumpur roche vitamin malaysia sdn madrid andreu roche sa madrid bhd kuala lumpur mexico productos syntex roche sa madrid roche diag roche sa de cv mexico city syntex nostics sl barcelona boehringer sa de cv mexico city grupo roche mannheim roche sa madrid sweden syntex de mxico sa de cv mexico roche ab stockholm roche diagnos city lakeside de mxico sa de cv tics scandinavia ab bromma taiwan mexico city moroccoproduit roche roche products ltd taipei roche diag sa casablanca netherland roche nostics ltd taipei roche vitamin pharmholde bv mijdrecht roche taiwan limit taipei thailand roche nederland bv mijdrecht roche diag thailand limited bangkok rovithai nostics nederland bv almere new limited bangkok roche diagnostic zealand roche product new zealand thailand limited bangkok turkey limited auckland roche vitamin new roche mstahzarlar sanayi anonim zealand limited auckland roche sirketi istanbul roche diagnostik sis diagnostic new zealand pty ltd auck temleri ticaret istanbul uruguay land nicaragua producto roche roche international ltd montevideo nicaragua sa managua norway sapac corporation ltd montevideo roche norge oslo pakistan roche usa roche holdings inc wilmington pakistan ltd karachi panama produc delaware hoffmannlaroche inc tos roche interamericana sa panama nutley new jersey rochelaboratorie city producto roche panam sa inc nutley new jersey roche vitamin panama city peru productos roche inc parsippany new jersey roche qumica farmacutica sa lima philip molecular systems inc pleasanton pine roche philippines inc makati california american roche interna roche vitamin philippines inc manila tional inc little fall new jersey roche poland roche polska sp z oo warsaw carolina inc florence south carolina roche diagnostic polska sp z oo genentech inc south san francisco warsaw roche witaminy polska sp california syntex usa llc palo zoo mszczonw portugal roche far alto california roche colorado corpo macutica qumica lda amadora roche ration boulder colorado bayer sistemas de diagnsticos sociedade roche llc morristown new jersey unipessoal lda lindaavelha puerto laboratory corporation america rico syntex puerto rico inc humacao holdings burlington north carolina russia roche moscow ltd moscow roche diagnostic corporation indiana singapore roche singapore pte ltd polis indiana venezuela productos singapore roche diagnostic asia roche sa caracas pacific pte ltd singapore roche vita min asia pacific pte ltd singapore south africa roche product proprie operating subsidiary associate company publish f hoffmannla roche ltd basel switzerland tel fax medium office corporate communication basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publication email baselwebmasterrochecom trademark mention enjoy legal protection roche annual report publish german annual general meeting original language english april roche annual report issue f hoffmannla roche ltd basel corporate communication design wirz identity ag zurich typeset staufferfebel ag basel lithos photolitho sturm ag muttenzbasel printer birkhusergbc ag graphische unternehmen reinachbasel bind buchbinderei grollimund ag reinachbasel cover background picture show computerassiste molecular modelling active ingredient herceptin drug treatment breast cancervitamin fine chemical diagnostic sale division pharmaceutical latin america asia sales region europe north america vitamin fine chemical diagnostic employee division pharmaceutical latin america asia employees region north america europe adjust basis